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ABSTRACT
The widespread availability of antimicrobial chemotherapeutics over the last half
of the twentieth century has offered dramatic increases in life expectancy. Unfortunately,
many pathogenic agents are exhibiting ever increasing resistance to many frontline
antibiotics. New chemotherapeutic agents are urgently needed to combat this threat; this
work seeks to illustrate applications in which mass spectrometric techniques may be
applied to the investigation of novel, small molecule chemotherapeutics for the treatment
of bacterial infections. Chapter 1 contains an introduction to mass spectrometry, as well
as an overview of relevant chromatographic techniques. Chapter 2 introduces the
bacterium F tularensis and M ulcerans and details the MS based investigation of their
secreted virulence factors. Chapter 3 introduces a human pathogen of particular concern,
M tuberculosis, and contains a detailed reporting on the MS based investigation of
internally synthesized compounds for the treatment of latent Tb.
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PREFACE
I have always had an interest in the electromechanical aspects of technology. I
remember in the 5th grade my father returned from work with a large box containing the
remains of a number of derelict computers. These 8086’s were obsolete even by 1991
standards but my dad simply said, “I thought you might have fun playing with these” and
handed me the box with a smile. It took me a few weeks but soon enough I sat in front of
the monochrome amber glow of a fully functional computer. Since that day I have had a
profound interest in electronics. I have assembled numerous computers since but none
have elicited such fond memories as playing Zaxxon on what entered my possession as a
box bound for the dumpster.
In a freshman general chemistry class I was introduced to concept mass
spectrometry (MS). MS would soon serve to combine my lifelong interest in computers
and electronics to my new love of chemistry. Upon receiving my undergraduate in
chemistry I continued to develop my interest in mass spectrometer entering Dr. Richard E
Lee’s laboratory in pursuit of a PhD in Bioanalytical Chemistry from the University of
Tennessee College of Graduate Health Sciences of which this work serves as the
conclusion.
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CHAPTER 1.

INTRODUCTION TO MASS SPECTROMETERY

The Early History of Mass Spectrometry
In most scientific programs mass spectrometry (MS) falls largely under the guise
of analytical chemistry.1 However the early history of MS is predominately the story of
physics,2 more precisely the story of the electron.3 By the late 1860’s physicists had
become increasingly interested in a strange phenomenon by which fluorescence could be
observed around the cathode of electrochemical reaction vessels.4 While many in the
physics community were investigating the nature of cathode rays, there still existed great
uncertainty as to their physical composition.5
Early in his career, J.J Thomson, worked to investigate the laws which governed
the transmission of electricity through gas and became interested in the propagation and
composition of cathode rays.6 Convinced the observed fluorescence must be attributable
to the interaction of an invisible force with the glass container,7 Thomson set out to
design an apparatus capable of measuring this unknown force.8 This instrument, the first
mass spectrometer, was used to measure the mass-to-charge ratio (m/z) of hydrogen gas
as early as 1899.9
Thomson continued to improve his spectrometer leading him to the discovery of
the electron, the elementary particle responsible for the propagation of cathode rays, for
which he would receive the Nobel Prize in Physics in 1906.10 Thomson, assisted by
Francis Aston, continued to study the ability of magnetic and electric fields to influence
the propagation of positive ions formed by electric discharge.11 This work led to the
generation of the first molecular mass spectra by positive ray spectrograph.12 While
Aston and his colleagues used the new instruments to investigate chemical entities, they
were primarily concerned with developing MS as to tool to tease out the physical
composition of the atom.13
While the early years of MS were concerned with answering larger, theoretical
questions, the dawn of World War II united many early MS pioneers together under one
banner.2, 14 Could MS prove to be a viable method by which to isolate the gaseous
isotopes of uranium? In 1939, Albert Nier effectively answered this question by
accumulating nanogram quantities of 252Pu using a magnetic sector MS of his own design
located at the University of Minnesota.15 Using this data, calutrons were constructed at
what is today Oak Ridge National Laboratories, to perform the bomb scale separation of
235
U from its parent 238U.
Magnetic sectors are based upon the realization that electric and magnetic fields
may be used to influence the trajectory of a charged gaseous (ionic) species in a sufficient
vacuum as to avoid kinetic interactions (collisions).16 While Thompson’s MS employed
high voltages to manipulate ions, the decoupling of the electrical and magnetic
components proved instrumental in the design of practical spectrometers.17 While the
physics of MS remains unchanged from Thompson’s first prototypes (the lighter the
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molecule, the greater the deflection) sectors were the first to influence ion trajectory
based upon the duality inherent to the Lorentz Force Law.18
Equation 1

Lorentz Force Law

F = Q( E + v × B)
By definition; a Lorentz force is point charge due to the perturbation of an
electromagnetic field.(Whereas F is the force applied to the ion, Q is the charge expressed
by a particle, E denotes the contribution of an electric field, B the contribution of the
magnetic field and v represents velocity)
Equation 2

Electric Component of Lorentz Force (Electric Sector)

F = qE
One of Thompson’s greatest contributions to the advancement of magnetic sector
instruments was his realization electric and magnetic fields may be used to differentially
influence the trajectory of an ion (the principal concept on which the QMA was later
built). (F again represents force, lower case q represents a component of the particle
charge Q, while E denotes the electric field.)
Equation 3

Magnetic Component of Lorentz Force (Magnetic Sector)

F = qvB
F again represents force, lower case q represents a component of the particle
charge Q, while v denotes velocity and B the magnetic field.
Equation 4

Newton’s Second Law

F =m

dv
= ma
dt

As even the most rapidly traveling ions in a mass spectrometer fail to even
encroach upon relativistic velocities, the second law may be expressed quite simply.
(Whereas F is again representative of applied force, m denotes the mass of the ion and
represents acceleration.)

2

Equation 5

Classic Motion of Charged Particles

(m / Q)a = E + v × B
The substitution of Equation 1 functionalized for net charge.
Equation 6

Substitution of Q

z = Q/e
As written. this equation technically equates mass number to the number of
elementary charges (e) in the case of mass spectrometry;, the localization of charge is
often considered to be inconsequential, allowing for the direct substitution of the formally
unconstrained charge number (z).
Equation 7

Motion of Charged Particles

(m / z )a = E + v × B
By war’s end, multiple discrete sectors had been assembled into hyphenated
spectrometers.19 Composite sector MS proved a significant advance in resolution as ions
of interest could be preselected in the first field,20 then further resolved using subsequent
sectors. In this way composite sectors were able to offer the performance of more modern
spectrometers before the technology existed to operate quadrupoles.21
Mass Spectrometry as a Tool for Chemical Investigation
The mid 1940’s saw the first commercialization of magnetic sector based
instruments.22 These early commercial sectors differed from the pioneering designs of
Neir in their use of electron ionization.23 While previous MS relied predominately upon
an arc discharge for the generation of ions, commercial instruments relied upon the more
robust electron ionization sources.24 Electron ionization (EI) mass spectra were found to
be informatically superior to those of arc discharge (AD).25 The highly uniform nature of
EI allowed for the formation of the first MS spectral libraries.26
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Equation 8

Representation of Gas Phase Electron Ionization

M + e − → M + • + 2e −
In this representation, M denotes the molecular analyte, e- the accelerated electron
and M the newly ionized analyte.
+

While advances in EI gaseous ion spectrometry continued throughout the late
1940’s, the incompatibility of MS with liquid analyses limited the widespread adoption
of the technique.27 In many ways the advancement of MS stalled, as other analytical
techniques were considered less troublesome.28 It required the commercial introduction
of gas chromatography in the early 1950’s to renew interest in MS as a chromatographic
detector29. Though initially problematic, the interface of gas chromatography and mass
spectrometry proved to be ideal.30 A sample could be prepared in a volatile solvent and
injected into the GC, which desolvated the analyte and delivered it to the MS in a gaseous
form. While GC had limitations (sample volatility), EI-GC/MS served to renew interest
in MS development.31 As GC continued to develop, the need for faster, lower cost
spectrometers became apparent.32
Equation 9

Potential Energy of an Ion in an Electric Field

E P = qU
In this equation Ep represents potential energy, q the fractional charge of the
particle and U denotes voltage (difference in potential between anode and cathode)
Equation 10

Kinetic Energy of an Ion in an Electric Field

1
Ek = mv 2
2
From Equation 9, if a charged particle at rest encounters voltage (U)(as is the case
in a time-of-flight mass spectrometer) the potential energy of the particle will be
completely converted to kinetic energy (Equation 10) Whereas Ek represents the kinetic
energy of an ion, m denotes mass and v represents velocity.
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Equation 11

Ionic Energy as a Function of Time
1
𝑑 2
𝐸𝑝 = 𝐸𝑘 = 𝑚 � � = 𝑞𝑈
2
𝑡

In the TOF-MS the potential energy of an ion is converted to kinetic energy
making Ep and Ek effectively equal. In a TOF the ion will experience an intense moment
of acceleration, and then its resultant velocity will remain unchanged for the remainder of
its flight down the RF free section of the flight tube. In this way the velocity of a ion as it
travels through the flight tube may be determined as the path length (distance, d) and the
time of flight, t, may be easily measured.
Equation 12

Ionic Energy as Expressed by Flight Time
𝑡=

𝑑

𝑚
𝑚
� = 𝑘�
𝑞
√2𝑈 𝑞

Essentially a rearrangement of Equation 11 expressed as an extrinsic function of
flight time. As distance (d) and potential (U) are functions of instrument design they may
be considered as constants and directly substituted for (k) as it denotes proportionality.
Equation 13

Generic Time-of-Flight Equation
𝑚
𝑧

𝑡 = 𝑘�

As in previous examples the empiric charge state (q) may be directly subsisted for
the less constrained z, yielding this familiar expression.
Throughout the early 1950’s the speed of single scanning sectors greatly limited
their ability to interface with GC,33 while the expense associated with most composite
sectors remained prohibitively high.34 A number of the new time-of-flight (TOF)
spectrometers were constructed and reported by 1956.35 The goal of the early TOF
designers was to create an instrument with the performance characteristics of a composite
sector but with a higher scanning speed and at a lower cost.36 The theory governing the
operation of a TOF is quite similar to that of a sector, though it relies on time not force to
afford separation.37 The key to the TOF’s speed and cost savings was its amazing
simplicity. Early TOF mass analyzers consisted of only a small accelerator, a length of
evacuated tubing terminating in a faraday cup, itself connected to an oscilloscope.38
In a TOF mass spectrometer all incoming ions are accelerated by a known electric
field, converting the ions potential energy to kinetic energy.39 These energized ions fly
into a field–free drift tube under high vacuum where separation occurs based upon a
particles velocity. In this way a particles velocity may be very accurately measured based
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upon the time required to complete the “flight” to the detector.40 The function of a TOF is
in many ways analogous to a very accurate clock. The TOFs robustness, GC
compatibility41 and relatively low operating cost (sectors consume a great deal of
electricity) coupled with the development of a compatible fast atom bombardment
ionization source42 secured the TOF-MS tenure in many analytical laboratories.
During the mid-1970’s and early 1980’s a number significant advances served to
again rejuvenate MS as GC had done 2 decades prior: the commercialization and
widespread adoption of reverse-phase high pressure liquid chromatography43 (HPLC), the
development of electrospray ionization (ESI)44 by John Fenn and the widespread
availability of computerized electronics facilitating the miniaturization of quadrupoles.45
As with GC before it, the coupling of LC to MS initially proved difficult, as the high
vacuums necessary for MS were physically incompatible with the LC’s liquid elutant. In
1989 John Fenn described the construction of an ESI source for the “mass spectrometry
of large biomolecules.”46
Analytes dissolved into a volatile organic solvent were introduced by a low
pressure pump to Fenn’s ESI source.47 The analyte was then dispersed into a fine spray
upon exit of the electrified capillary. The “electrospray” would then be subjected to
continued desolvation. As the size of the droplets continues to decrease the density of
their electric field intensifies.48 Like charges began to repel one another, greatly
increasing the surface tension of the particle. At some point (Rayleigh limit), the particle
can no longer tolerate this increase in tension and dissociates in smaller droplets of
discrete positive and negative charge. This cycle of evaporation, charge increase,
repulsion and (Coulombic) explosion continues until only carrier-free molecular ions
remain.49
ESI provided a means to rapidly desolvate the LC elutant, and avoided damage to
the vacuum system of the MS. While GC/MS precluded the investigation of most nonvolatile analytes, many common pharmaceutical and industrial materials were found to be
compatible with LC/ESI-MS based analysis.50 Though the Fenn source was constructed
for the investigation of macromolecules, lessons gleaned through its design and operation
were quickly applied on a commercial scale to the investigation of large and small
molecules alike.51
The early 1980’s also witnessed the commercialization of spectrometers based
upon Wolfgang Paul’s Quadrupole Ion Trap52 (QIT) as well as the widespread
availability of MS systems based upon the relatively low cost quadrupole mass
analyzer53(QMA). While QMA based instruments are generally referred to as mass
spectrometers, their function is more analogous to that of a mass filter than of a
conventional MS.54 In the QMA, ions within a relatively narrow mass window (+/- 1
amu) are allowed to pass through the quadrupole while ions outside the window are
effectively filtered out. In this way a QMA emulates the function of a true mass
spectrometer by rapidly sweeping its’ small bandpass region across a broader scale.55
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In addition to its relatively low cost, QMAs offer a number of advantages over
traditional sectors and TOFs in applications where high mass accuracy is unnecessary.
The small size of the QMA allows for the ion source and detector to remain in close
proximity (as little as 12 cm) while the strong “saddle field” effects allow the analyzer to
operate at vacuum levels more easily achievable in the common laboratory56 (3 x 10-5
Torr). The typical QMA consist of four circular electrodes positioned in a radial array, at
a distance proportional to their hyperbolic cross section (Equation 14). The QMA is then
utilized through the application of alternating time dependant direct current (DC) and
time-independent alternating current (AC) electric potentials.57
Equation 14

Approximation of Ideal Quadrupole Field Radius
𝑟 = 1.148 𝑟0

While no man-made hyperbolic field may be considered ideal, over forty-five
years of instrument design have suggested Equation 14 as the most appropriate geometry
for the construction of a quadrupole hyperbolic array. Whereas r represents the radius of
the electrodes and ro the effective quadrupole field radius
The rapidly alternating electric potentials localized around the hyperbolic
electrodes serve to influence the flight of ionic species introduced into the QMA.* While
the electrical gradients refresh at a very high frequency (>2kHz), an effort can be made to
visualize a single electronic rotation responsible for the eventual generation of the
QMA’s saddle field.58 It is common practice to describe ionic trajectories in terms of
vectors, by convention X and Y describe the ions location relative to the cross-section of
the electrode array while Z represents the distance the ion has traveled down the length of
the analyzer. To aid in the conceptualization of this electromagnetic phenomenon the XY and X-Z influences will be considered separately, also, an attempt will be made to
separate the time-dependant (alternating) and time-independent (direct) electronic
influences into their principal components.
When an AC voltage is applied to an electrode pair, in the case the potential will
be applied to the X electrodes thereby influencing the trajectories of ions in an X-Z
orientation, each X electrode will spend half of the cycle positively charged while the
opposite electrode conveys a negative potential.59 In a conventional quadrupole, each of
the two electrode pairs (X &Y) remain 180o out of phase at all times, in this way when a
positive potential is conferred to one electrode, an identical negative charge is conferred
______
*While an effort has been made to introduce the mathematical basis of instruments until
this point, it would not be reasonable to introduce the advanced differential equations
governing the operation of the QMA given the already considerable length of this
chapter. For the concerned reader a number of articles are readily available which discuss
the quantum-mechanical principles of the quadrupole array in depth, including an
excellent piece by Philip Miller at the University of Arizona.60
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to the electrode spatially opposite. Should positively charged ions be introduced during
this electronic cycle, again only considering travel in the X-Z plane relative to the center
axis of the array, positively charged ions experiencing a net positive AC potential will be
repelled (focused) towards the center of the quadrupole.61
As the array exists in phased equilibrium, the inverse is also true, when a negative
potential is expressed the positive ions will be attracted towards the negatively charged
poles, effectively defocusing the ion beam.62 Should the defocusing interval be sufficient
in duration, the positively charged ions will eventually collide with the negatively
charged electrode and be excluded from the ion beam.63 In this way the ionic trajectories
through a QMA may be influenced both by the perturbation of the electronic potentials
expressed by the electrodes and by the duration of those potentials.
The Y-plane, time independent DC electrodes serve to compliment the focusing
action of the X-plane to perturb the flight of ions in a mass dependent fashion.64 When
the alternating and direct potentials are evaluated in concert with time, the mass focusing
properties of the QMA began to become evident. Should an amalgam of ions be
introduced into the array, the light and heavy species would interact with the electronic
gradients quite differently. If an ion is quite heavy, its resultant momentum (trajectory)
will be largely unaffected by rapid perturbations of the electronic gradient and the ion
will only feel the net effect of the electric potential.
Due to the conservation of momentum, heavy ions tend only to be effected by
time independent forces.65 Conversely, very light ions will be significantly perturbed by
very rapid (time-dependent) oscillation of the electric gradient in the array. In fact, small
ions may be accelerated rapidly enough to exit the ion beam entirely and collide with the
oppositely charged electrode, thus being effectively mitigated from detection. In this way
a QMA is capable of excluding ions above or below a critical value based upon the speed
at which an ion can respond to the defocusing potential exerted upon it.66 The undesirable
ions are allowed to collide with the electrodes and be excluded from the ion beam while
ions of a desired mass are allowed to traverse the array and be counted by the detector.67
Many modern analytical laboratories now rely on the implementation of
hyphenated or hybrid mass spectrometers.68 In this way, scientists are able to overcome
many of the physical limitations inherent to a single spectrometer type. While in no way a
modern implementation, the quadrupole-TOF remains the centerpiece of many small
molecule and proteomic laboratories alike and is responsible for a great deal of the data
outlined in this work.
Introduction to Chromatography
The term “Chromatography” has come to be synonymous with numerous
laboratory techniques employed in the separation of mixtures.69 In the most generic of
terms, the analyte of interest is introduced into a liquid (LC) or gas (GC) mobile phase
which serves to transport the sample through a structurally constrained stationary phase.
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The analyte is then separated into its principal components as some compounds are
capable of migrating through the stationary chemistry more rapidly than others.70 The
speed at which an analyte achieves equilibrium between chromatographic phases and is
ultimately eluted from the chromatographic column (retention time) is largely a function
of a compounds physical-chemical properties, which in the case of separation sciences, is
often expressed as a partition coefficient.71
Gas Chromatography
A typical gas chromatograph consists of a carrier gas source, a sample injector, a
column (contained in an oven) and some means of detection.72 While derivatization
techniques exist, analytes are generally considered to be GC compatible if they possess a
relatively low boiling point (<250oC) and they do not tend to undergo thermal
decomposition (non-thermolabile).73 In GC the analyte is dissolved into a low-boiling
solvent (such as CH3OH) and is introduced to a heated injector. Upon injection the
solvent is immediately evaporated yielding an injection chamber filled with nebulized
analyte and residual injection solvent.74 A carrier gas (mobile phase) then transports the
vaporized analyte/solvent matrix into the chromatographic column housed in a high
temperature oven. The column serves to structurally support the chromatographic
stationary phase to which the analyte/solvent matrix is introduced at the column head.75
Two types of oven programs are often used to achieve analytical separation; isothermal
and thermal gradient. In an isothermal program the oven (and the column it contains) are
preheated to a temperature at which the analyte of interest will be retained (equilibrate
with the stationary phase) while the solvent matrix will be virtually unretained and eluted
rapidly.76
In the case of a thermal gradient, the oven is set to a sufficiently low temperature
to allow the analyte/solvent matrix to initially equilibrate with the stationary phase. The
oven is the heated in a controlled fashion with the solvent eluting first followed by the
analytes of interest, the use of a thermal gradient often aids in the mitigation of solvent
diffusion effects often seen in isothermal runs however at the cost of increased
complexity.77 As the analytes are eluted from the column, the elutant is directed to some
form of detector.
The fifty plus year history of GC has seen numerous detection methodologies,
though today most pharmaceutical laboratories often rely primarily on a combination of
three,78 Flame Ionization Detector (FID), Electron Capture Detector (ECD) and MS. As
MS is the focus of the work only FID and ECD will be discussed briefly here.
Flame Ionization Detector
Today FID has established itself as a popular and robust detection method; it
relies upon the ability of a hydrogen/oxygen (air) flame to ionize organic molecules.
These ions are then directed across an adjacent electrode, the resultant ion current is
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directly proportional to the ions generated per unit time.79 The FID has a number of
endearing qualities; very low cost, minimal maintenance, no radionuclide, exceptional
linearity and dynamic range and a very reasonable sensitivity for carbon containing
compounds.80 For these reasons the FID has established itself as a near universal GC
detector, with many laboratories still relying on it heavily to this day.81
Electron Capture Detector
While much less common than the FID, the ECD enjoyed a significant success
throughout the history of GC.82 The ECD relies on the use of a β radiation source (63Ni)
and offers exceptional sensitivity in the detection of halogenated compounds.83 In an
ECD β particles are emitted into a makeup chamber filled with a continuous supply of
nitrogen.84 The low excitation energy of nitrogen allows the β particle to easily strip a
valence electron; these electrons collide with additional nitrogen atoms stripping
additional electrons resulting in a β particle induced electron cascade. These many
electrons are then attracted towards a positively charged anode generating an electric
potential. As the elutant is introduced into the detector, the analyte effectively disrupts
the flow of electrons and reduces the electric potential between the ECD’s cathode and
anode. This loss of voltage is proportional to the concentration of analyte in the detection
chamber at any given time. The ECD has been relied upon heavily in the past for the
detection of nitro, nitrile and halogenated compounds. While the ECD will likely remain
significantly utilized for the foreseeable future, regulatory difficulties arising from the
ECD’s reliance of radionuclides have led many laboratories to transition from ECD to
MS based instrumentation.85
Liquid Chromatography
The term “liquid chromatography” (LC) has come to encompass many different
separation techniques and technologies. Numerous LC methodologies have been utilized
in concert with mass spectrometry over the years,86 however none have had the impact of
high-performance liquid chromatography87 (HPLC). HPLC/MS has proven to be an
extremely powerful tool in the analysis of the pharmaceutical compounds.88,89
The typical HPLC consists of a one or more high pressure liquid pumps, a sample
injector (manual or automated) a chromatographic column (often contained in an oven)
and ultimately a means of detection.90 In this way the generalized schematic
representation if an HPLC is itself very similar to the GC before it. As the name implies,
the greatest contrasts between the modern HPLC and modern GC is the mobile phase
they employ and the means by which they ultimately achieve separation. While the GC
relied on a single gas to carry the analyte, the modern HPLC relies on a system of pumps
(minimally binary, often quaternary) to deliver a precisely mixed mobile phase.91 The
ability of an HPLC system to accurately dispense these solvents proves critical to the
robustness of the instrument.92 In the GC, the limited heat capacity of the gas coupled
with the low mass of the chromatographic capillary allowed separation to be repeatably

10

achieved by simply varying the temperature of the column oven.93 While many HPLC
instruments are now equipped with column ovens themselves, their function is more to
mitigate variations in laboratory temperature than to singularly achieve separation.
While variations on the classical methods exist, the HPLC generally achieves
separation through the use of a compositional gradient of a polar (often H2O) and organic
mobile phase.94 Most modern laboratory implementations of HPLC/MS for the analysis
of sample purity or composition begin with the analyte of interest being dissolved in a
small volume of compatible solvent95 (H2O, CH3OH, ACN)*. The chromatographic
column, containing the stationary phase, is allowed to initially equilibrate (both thermally
and compositionally) and the sample is introduced into a highly aqueous matrix. Over the
duration of the chromatographic run the composition of the mobile phase is slowly
ramped from a highly aqueous to that of a highly organic nature.96 During this process,
components of the analytical amalgam which were previously retained on the stationary
phase slowly become more compatible with the mobile phase, partition, proceeded
towards chromatographic equilibrium (begin migration) and are eventually eluted from
the stationary phase as separate species.97 These distinct chemical species are then
detected or analyzed (MS) to ultimately evaluate the effectiveness of the chromatic
process.
While in many ways the MS has become the most informatically rich detector
available to the typical analytical laboratory, most HPLC systems are equipped with
detection strategies complimentarily orthogonal to spectrometry. As many laboratories
are limited by both available instrument time and sample quantity many instrument
manufactures have made significant strides to provide systems capable of utilizing
multiple detection strategies during a single run.
Ultra-Violet/Visible Detector (UV/Vis)
UV/Vis is in many ways the most obvious compliment to the MS due to the
nondestructive nature of this detector. In a typical UV/Vis, the chromatographic elutant
enters the detector’s transparent flow cell where it is exposed to ultraviolet or visible
irradiation at a known wavelength.98 Analytes which contain π or non-bonding electrons
are able to absorb energy through the transitioning of electrons to higher anti-bonding
molecular orbitals.99 The absorption of energy can be recorded and spectra generated, in
concert, UV and MS spectra have proven to be a powerful tool in the analysis of
pharmaceutical compounds.
______
*As this introduction is largely devoted to mass spectrometry, reverse phase HPLC will
be introduced as it is vastly more compatible with traditional MS instrumentation than
other conventional elution systems.
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Evaporative Light Scattering Detector (ELSD)
While ELSD is a destructive analytical technique, it has gained great popularity
for its ability to evaluate many compounds which typically ionize poorly via MS.100 The
ELSD is also somewhat unique in its ability provide a relatively linear signal response
independent of the optical properties of the molecule analyzed, in contrast the Uv/Vis
was only compatible with analytes that contained an accessible chromophore.101 When
compared to a MS, the ELSD is quite simplistic. The elutant flow is introduced into the
ELSD nebulizer and mixed with large volumes of nitrogen gas to produce a diffuse
plume of effluent. The plume is then directed down a heated evaporation tube where the
remaining mobile phase is rapidly eliminated, leaving only diffuse particles of dried
analyte.102 The particles of dry analyte are directed through an optical chamber where
they occlude a high intensity light source. This loss of signal can be recorded and spectra
generated much as is the case with the Uv/Vis.
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CHAPTER 2.

HRMS BASED INVESTGATION OF BACTERIAL SECONDARY
METABOLITES
An Introduction to Bacterial Secondary Metabolites

Like their human hosts, pathogenic bacteria utilize a system of complex strategies
by which they obtain the nutrients and energy necessary for survival and reproduction.
Most bacteria assimilate the organic molecules they require to thrive from their
environment. In this way pathogenic bacteria reap organic molecules from their host
organism, consume the portion they require, and secrete the waste byproducts as primary
metabolites.103
By contrast, secondary metabolites are compounds produced not as a function of
survival, but as a function of competition. The list of known bacterial secondary
metabolites has become quite long, and have been used both primarily and as synthetic
scaffolds for; antibiotics (penicillin), pigments, immunomodulators (of which this chapter
is concerned), pesticides (pyrethrins) and antitumor agents.104 Two pathogenic
microorganisms of particular interest to our laboratory are Francisella tularensis and
Mycobacterium ulcerans (and will be introduced in detail later in this chapter.)
Decoupling of Nondestructive (NMR) and Destructive (MS) Analytical Techniques
While this chapter serves to illustrate two pathogens of particular concern to our
laboratory, the overarching goal of our bacterial natural product (BNP) effort was not
solely to investigate F tularensis and M ulcerans. The primary focus of these efforts was
to establish a universal means of profiling unknown bacterial natural products regardless
of their species of origin. The resulting workflows were designed in such a way as to
leverage nondestructive analytical techniques, such as crude extract NMR, to enable the
targeted application of destructive, more informatically rich techniques. The initial proton
and 2D crude lipid NMRs coupled with sample conserving analytical TLC provide
information on the chemical species contained in the BNP while selective TLC
developing agents, such as Sigma Phospray, can support and enumerate NMR results.
In this workflow data acquired through minimally invasive techniques can target
the application of HPLC or Flash chromatographic fractionation as well as conventional
UPLC/MS analysis depending on the quantity of sample available for analysis
(Figure 1). In the case of SchuS4, its highly virulent nature precluded the acquisition of
large analytical stocks. For this reason our workflow was updated to allow for the pooling
and serial concentration of analyte limited products (Figure 2). Once sufficient quantities
of analytical samples have been compiled, High Content NMR experiments (HSQC,
HMBC, COSY, NOESY) coupled with HRMS accurate masses can be applied to the
enumeration of potential chemical formula For this reason analytical techniques in this
section will be presented in order of chemical invasivity from the least destructive
(NMR) to the most destructive (FAME) techniques following our BNP protocols.
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Figure 1.
Pictorial Representation of SchuS4 BNP Analytical Workflow
Illustrating the Extraction, Separation and Analysis of Bacterial Natural Products
NOTES: SchuS4 / LVS were harvested and acetone soluble lipids (ASL) were removed
and dried. The dry ASL was redisolved in MeOH and deactivated silica 60 A (1g) added,
the resulting mixture was then evaporated to dryness via rotovap, the lipid impregnated
silica was transferred to the top of a 4 g HP-Sil (Biotage) cartridge for flash
chromatography using a eluent gradation of 90% CHCL3/ 10% CH3OH to 60% CHCL3/
40% CH3OH, all fractions were collected and content monitored via by TLC analysis.
The lipids potential for immune modulation of each fraction was bio-assayed, fractions
retaining biological activity were further analyzed using UPLC-qTOF.
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Figure 2.
Detailed Workflow for the Separation and Analysis of Product
Limited Francisella tularensis Extracts
NOTE: The addition of an offline sample store allows archival of analytical stocks until
sufficient concentrations have been achieved through serial fractionation and pooling
efforts.
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Introduction to Francisella tularensis
F tularensis (Ft) is a pathogenic gram-negative bacteria which causes the disease
Tularemia in humans. As the pathogen is readily transmissible by aerosol and highly
virulent it has been classified as a Class A Select Agent in the United States. Ft is also
unique from a metabolic tractability standpoint as the virulent SchuS4 strain and nonvirulent live vaccine strain (LVS) appears to retain very similar (though distinct) lipid
profiles. Recent work in the Bosio Laboratory at the National Institutes of Health has
shown lipid extracts from FT when administered to stimulated murine bone marrow
derived microphages (BMM) significantly attenuated the inflammatory cytokine
response. This attenuation suggested that the extracts from the SchuS4 strain contained
an immune suppressive substance. Interestingly, Ft lipids have also shown to elicit
protective immunity in MyD88 -/- mice through the surface expression of Lipid A
analogs.105 When separated into a ternary system via modified Folch106 partitioning, the
majority of the attenuating agent remains in the chloroform fraction, supporting the
hypothesis that SchuS4 lipids are important virulence factors (Figure 3).
Preliminary testing revealed the lipids from the virulent Ft SchuS4 strain
displayed a significant affinity for cytokine attenuation while similarly prepared lipids
from the attenuated Ft live vaccine strain (LVS) showed little to no effect. Initial samples
of dried lipid were suspended in CDCl3 and submitted for proton NMR (Figure 4). Small
lipid peaks may be resolved but the crude lipid was found to be highly contaminated with
bacterial cellular debris, 2D NMR also proved quite complex (Figure 5). The crude lipid
was separated via 2D TLC as well as fractionated by standard phase flash
chromatography in an attempt to reduce background contamination. A portion of the
fractionated materials were returned to NIH for testing, the areas of high activity were
pooled and further analyzed via LC/MS. Traditional and 2D TLC’s of Schus4 and LVS
lipid crudes were run using a semi-analytical technique (Figure 6) the bioattenuation
properties were then evaluated (Figure 7), this data provided us the ability to locate the
“most active” components for further “destructive” analysis.
Guided by cytokine deactivation potential of SchuS4 (Figure 8) as compared to
the LVS profile (Figure 9), fractions were concentrated into three pools. As fractions
were separated via normal phase silica gel chromatography the pools were generated
based upon the polarity of the analyte. The highly nonpolar (Fractions 4-5), the
moderately polar (Fractions 19-23) and the most polar (Fractions 28-34) pools were then
submitted for further analysis. (Figure 10) Following the BNP workflow lipid fraction
pools were first analyzed via nondestructive techniques (NMR, UV). These data were
then used to guide the application of more intrusive chemical analysis
(HPLC/MS)(GC/MS). Processed NMR and UPLC/MS spectra of the nonpolar pool are
illustrated below. Figure 11 is a processed spectra from 1024 scan proton NMR. After
primary fractionation the spectra remains complex though appears to contain significant
concentrations of saturated lipids (1-2 ppm) and reduced concentrations of unsaturated
lipid products (4.0-4.7 ppm). Figure 12 illustrates a processed 2D HSQC of this sample,
when compared to the unfractionated sample the fatty acid and phospholipid regions
appear to have increased relative to the aromatic component.
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Figure 3.
Activity of Modified Folch SchuS4 Partitioned Lipids with and
without Addition of the Cytokine Activating LPS, with the Chloroform Fractions
Predominately Responsible for Cytokine Attenuation
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Figure 4.
Complex Proton NMR Spectra of Crude SchuS4 Lipid Extract with
Lipid Signals Largely Masked
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Figure 5.

Complex 2D NMR of Crude SchuS4 Lipid Sample

NOTE: The fatty acid region remains highly complex.

19

6

8 7 5

3

4

2nd run
2

1

f irst run

Figure 6.

Illustration of Typical SchuS4 Lipid 2D TLC

NOTES: Black line indicates the point of origin; the analytes were first eluted in (12:6:1)
CHCl3:MeOH:H2O. The plate was rotated 90◦ and again separated via (10:6:4:1)
THF:1,2-Dimethoxymethane:MeOH:1M NH4OH.
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Figure 7.

Bioanalysis of SchuS4 2D TLC Bands (B1-B5) at 1:100 and 1:300.

NOTE: Dilutions indicate TLC Band 1 retains significant cytokine attenuation potential
in primary murine BMM cells.
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Figure 8.
Cytokine Deactivation Potential of Initial Flash Chromatographic
Fractions of SchuS4 Lipid Extract
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Figure 9.
Cytokine Deactivation Potential of Initial Flash Chromatographic
Fractions of LVS Lipid Extract
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Figure 10.
Cytokine Deactivation Potential of Initial Flash Chromatographic
Fractions of SchuS4 Lipid Extract Illustrating Three Areas of Activity
NOTE: Fractions 4-5, 19-23 and 28-34 were pooled for further analysis.
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Figure 11.

1024 Scan Proton NMR of Pooled SchuS4 Fractions 20-24

NOTE: The saturated and unsaturated regions of the spectra remain highly complex.
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Figure 12.
2D HSQC of Pooled SchuS4 Fractions 20-24 Depicting the
Enrichment of Fatty Acids and Phospholipids
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Fatty Acid Methyl Ester Derivatization and GC/MS Analysis
As many of these experiments predated our laboratories acquisition of a HRMS,
Figure 13 depicts a processed UPLC-SQD spectrum of the concentrated nonpolar lipid
pools of LVS and ScghuS4 lipid. The peaks at 581.2 m/z (butylstyrene) and 463.3 m/z
(polypropylene)(Figure 14) appear to be highly significant but were later determined to
be common laboratory contamination. Additional analysis revealed lipids were likey
present in the very polar pool however they appeared to be poorly ionizable and similarly
contaminated via ESI-LC/MS (Figure 15). At this point in the investigation a decision
was made to temporally discontinue the use of LC/MS in favor a of GC/MS based fatty
acid methyl ester (FAME) workflow as the derivatization process (HCl-MeOH or KOH)
would largely disregard the observed laboratory contamination.
Fatty Acid Methyl Esterification GC/MS analysis enabled direct evaluation of
SchuS4 and LVS matched acetone soluble lipid (ASL) crude lipid samples without the
sample diminishing chromatographic step. Methyl esters of the ASL lipid crudes were
prepared by transesterification using HCl-CH3OH or base catalyzed (KOH or TBAH)
iodomethane methylation. The resultant spectra were analyzed by GCMS using a BD-225
column and 42 minute thermal gradient from 90◦ to 220◦C. Elutant peaks were compared
to NIST spectral database for peak identification. Upon comparison the SchuS4 and LVS
spectra are quite similar (The LVS Peak 8 tailing is due to the aforementioned preexisting
contamination) except for the large decanoic acid peak (2) completely absent from the
LVS sample. The processed spectra for LVS (Figure 16), SchuS4 (Figure 17) and
composite LVS/SchuS4 (Figure 18) are presented below.
The results from the TBAH derivatization largely confirmed the results from the
acidic experiments; peak 2 appeared to be significantly larger in the virulent strain, while
peak 4 appears to be significant enlarged in LVS. The processed spectra for LVS (Figure
19), SchuS4 (Figure 20) and composite LVS/SchuS4 (Figure 21) are presented below.
Peaks A-D corresponds with the butyl esters of previously identified compounds. The
TBAH difference maps (Figure 22 and Appendix B) also suggest that SchuS4 may be
additionally enriching tetra and octadecenoic acid components of its lipid membrane.
Upon further investigation, decanoic acidtetradecanal is generally accepted to be a
function of bacterial membrane plasticity generally associated with bacterial remodeling
of the lipid membranes in response to temperature (as temperature decreases the
bacterium installs shorter chained lipids to maintain membrane plasticity).107
Ft Lipid Conclusions and Discussion
The purpose of the original lipid workflow was to use nondestructive means to
more accurately target more destructive analytical techniques. The single and multidimension NMR work illustrated the lipids of interest resided in a complex matrix of
cellular and laboratory contamination. The use of semi-preparative LC allowed lipid
fractions to be tested discretely; however, the absolute recovery suffered greatly as the
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Figure 13
Serial Concentration UPLC/MS of Non-polar LVS (Top) and SchuS4
(Bottom) Fraction Pools
NOTE: The two significant SchuS4 peaks at 581.4 m/z (Butylstyrene) and 463.3 m/z
(Polypropylene) were determined to be laboratory contaminates.
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Figure 14.
Extracted Spectra from TR 4.323 (463.3 m/z) Δ 44m/z Indicative of
Polypropylene Contamination
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Figure 15.
The Data Directed (MSe) TIC of SchuS4 Fractions 29-34 Displayed
Similar Contamination
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Figure 16.
GC/MS Spectra of HCl-CH3OH Fatty Acid Methyl Ester
Transesterification Products of LVS Acetone Soluble Lipid Extract
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Figure 17.
GC/MS Spectra of HCl-CH3OH Fatty Acid Methyl Ester
Transesterification Products of SchuS4 Acetone Soluble Lipid Extract
NOTE: Peak two is of particular interest.
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Figure 18.
Composite of GC/MS (HCl-MeOH) Fatty Acid Methyl Ester
Transesterification Products of SchuS4 (Positive) and LVS (Negative) Acetone
Soluble Lipid Extracts
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Figure 19.
GC/MS Spectra of Base Catalyzed (TBAH) FAME Products of LVS
Acetone Soluble Lipid Extract
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Figure 20.
GC/MS Spectra of Base Catalyzed (TBAH) FAME Products of
SchuS4 Acetone Soluble Lipid Extract
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Figure 21.
Composite of Base Catalyzed (TBAH) FAME Products of LVS
(Positive) and SchuS4 (Negative) Acetone Soluble Lipid Extracts
NOTE: Difference maps were normalized for tetradecanoate.

36

Figure 22.
GC/MS (KOH) Fatty Acid Methyl Ester Transesterification Products
of SchuS4 (Positive) and LVS (Negative) Acetone Soluble Lipid Extracts Normalized
for Tetradecanoate
NOTES: In an attempt to futher validate SchuS4’s proposed enrichment of peak two, a
KOH supponification was attempted. Upon investigation, the only meaningful difference
was in docosanoic acid (Peak 11)--further suggesting some divergences in the lipid
profiles of the bacteria are likely resultant from differences in their environment (BSL2
vs BSL3).
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analytes are moderately soluble at best. The GC work served to illustrate a number of
interesting results, SchuS4 expresses significantly more short chained (12:0/14:0) acids,
while LVS appears to express longer chains (18:0). While a portion of this expression is
likely a result of membrane homeostasis, it is interesting to note Lipid A surface
expresses predominately (18:0) and Lipid A mutation has shown to play an important
role in potentially protecting immune compromised mice.105
TLC/LTQ-MS experiments were designed and are currently underway to
determine if the methyl esters identified via GC are part of a larger conjugated molecule
(Lipid A) or if they exist as smaller free lipid species.
One of our primary goals in the design and implementation of the SchuS4 / LVS
lipid analytical workflows was to leverage a number of nondestructive analytical
techniques to target destructive, though informatically rich, mass spectrometric analyses.
The preliminary NMR and TLC data provided considerable data including the presence
of fatty acid components and common laboratory contaminates. In retrospect, as the LVS
lipid components are expressed and purified in standard laboratory glassware (BSL1+)
while the growth of virulent SchuS4 requires elevated precautionary measures (BSL3+) a
few of which are the exclusion of glassware and use of plastic cultureware, a certain level
of plastics and plasticizer contamination in the SchuS4 extracts was unavoidable.
Initially we sought to overcome this contamination through the use of semipreparatory flash chromatography. Three pools of SchuS4 fractions retained tractable
activity upon separation, however the limited solubility if the lipid products greatly
diminished recovery. We realized from the outset any chromatographic system would
afford analytical losses. Our hope was the acquisition of highly meaningful correlational
2D NMR would prove the sacrifice worthwhile. Unfortunately the 2D spectra remained
highly complex and inappropriate for correlational spectroscopy, as multiple peaks
overlapped in key areas.
The GC transesterification proved highly successful to study lipid content as it
required little analyte and the chemical derivatization and chromatographic separations
removed many of the existing contaminates. The discovery of the short chain fatty acids
(SCFA) found only in the SchuS4 extract is thought to be highly significant.
The question now is to determine if these SCFA lipids exist on their own functioning as
immunesuppressive agents or if they are conjugated into macromolecules for example
Lipid A or if both may be true. The biological basis for either chemical theory appears
conceivable as the limited genetic material available (2.3 Mb) suggest Ft is genetically
unable to afford many of the more advanced defense mechanisms via the synthesis of
complex polyketides or non-ribosomal peptides as witnessed in larger pathogens such as
P. aeruginosa and M. ulcerans.
Over its evolutionary history as a pathogen Ft has developed many tools to
subvert host immune response. The question now is do host immune bodies fail to
recognize the impending threat? Or are they somehow deactivated through a small
molecule modulator? The surface expressed lipid A head of LPS is a primary determinant
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of antigenic response to gram negative bacteria. A recent publication noted Ft’s ability to
remodel Lipid A.105 If the Lipid A antigen were adapted to express SC fatty acids as
opposed to the more usual 18:0 and 20:0 systems it is interesting to hypothesis that the
host immune bodies via innate Toll signaling pathway may not be activated by virulent
strains of Ft, at least for a time.
To this end a TLC/Direct Injection LTQ-MS experiment was developed in an
attempt to conclusively identify the SCFA conjugation products of Ft SchuS4. While we
only have preliminary data at this time, the initial results appear to confirm the
experimental design. The phosphatidylethanolamine (Figure 23) head group contains
seven carbons, the spectra indicates 32 to 36 total carbon (Figure 24), as there are
generally symmetric-2 lipid prosthetics the lipid moieties appear to range from 10 to 14
carbons in length supporting results from our GC-MS analysis. We have also identified
phosphotidylcholine (Figure 25) though it displays a more usual lipid chain length.108
Development of a Generic Bacterial Natural Product Analytical Workflow with
Applications from the Analysis of Mycolactone
The analysis of bacterial natural products (BNPs) presents a number of somewhat
unique challenges to the laboratory chemist, many due to the amazing diversity inherent
to NP libraries. While no consolidated BNP evaluation workflow currently exists, there
are a number of proven analytical techniques directly compatible to work in BNP
isolation and classification. An unfortunate caveat exists throughout many of these
analyses, however, in that a pure analytical sample is predominantly required to generate
meaningful data. To this end, many BNP workflows are subdivided into two primary
components; purification and analysis.
The primary focus of our purification technique is to separate the unknown
complex fraction into multiple, reasonably pure fractions, while recovering as much of
the initial analyte as possible. Conceptually, this technique may be applied in one of two
ways; the bulk fractionation of a complex mixture (as is often the case when working
with large quantities of crude material or in industrial applications) or an analytically
driven “targeted fractionation” approach. Given the relatively limited quantity of analyte,
a target driven fractionation approach appears to be the most prudent.
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Figure 24.

LTQ-MS of Phosphatidylethanolamine
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Figure 25.

LTQ-MS of Phosphotidylcholine
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The primary focus of our purification technique is to separate the unknown
complex fraction into multiple, reasonably pure fractions, while recovering as much of
the initial analyte as possible. Conceptually, this technique may be applied in one of two
ways; the bulk fractionation of a complex mixture (as is often the case when working
with large quantities of crude material or in industrial applications) or an analytically
driven “targeted fractionation” approach. Given the relatively limited quantity of analyte,
a target driven fractionation approach appears to be the most prudent.
As the fraction of interest appears to contain a chemical species affording high
activity against a particular bioassay, a bioactivity driven secondary fractionation may
offer the best odds of identifying the active compound, also as the identity of the plant is
known, a literature search may be useful in identifying previously isolated active
components. Over the past two years, our lab has taken interest in the bioactivity driven
fractionation of naturally derived compounds, if a selective bioassay exists, they often
afford levels of detection far superior to traditional analytically driven techniques.
Some limited MS data can be greatly helpful in preparing for a secondary
fractionation run. A small aliquot of material sampled on the HRMS in both ESI(+) and
ESI(-) full scanning mode offers insight into compound polarity (this aided by initial
fractionation conditions and elution time) apparent ionization efficiency and fraction
complexity. In a somewhat method and analyte dependent fashion, the pKa of a
compound may be estimated by comparing its elution time against a series of known
compounds, in much the same way as gel based systems use molecular weight “ladders”
to qualitatively identify the molecular mass of an unknown protein. While single point
data may provide useful, these estimations become more robust with the inclusion of
orthogonally referenced elutions. Aided by these estimations, the empirically measured
high resolution mass data can be used to predict prospective chemical formula for the
NPs while the UV detector offers secondary detection of compounds containing
accessible UV chromophores.
The secondary fraction of a BNP is conceptually quite simple but often difficult to
achieve in a laboratory setting. The hope is to separate the BNPs using a method more or
less orthogonal to the original (Standard Phase CHCl3:CH3OH) fractionation conditions.
We have evaluated a number of semi-analytical chromatographic conditions for their
ability to provide selectivity contrasting with CHCl3:CH3OH separations. While HILIC is
often referenced as a hybrid of conventional and reverse phase chromatographic
techniques (for its reversal of conventional RP elution orders) we have been unable to
achieve reasonable recoveries with this technology.
In our laboratory we have relied on Phenomenex pentafluorophenyl (PFP)
stationary phase chemistries to provide a somewhat contrasting separation technique
compared to conventional C18 (PFP is a reverse phase column and uses mobile phases
similar to C18 but is specially hybridized by the inclusion of a polar-cyclic
pentafluorophenyl motif that differentially retains many of the aromatic and polar
compounds often encountered in natural products). While we have found success using
this type of secondary fractionation, especially when the samples are not overly complex,
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I feel the investigation of a truly orthogonal separation technique is warranted and will
increase the robustness of any subsequent BNP publications. To this end, I am currently
investigating semi-analytical SFC based techniques for their potential application to our
BNP workflow.
Both techniques offer potentially complimentary selectivity, however, I have
found many of my standard phase BNP separations often offer low recoveries when
analytes are in the milligram range, we have recently acquired low volume (4 gram)
deactivated silica columns for use with our isolera flash chromatography systems which
should aid in sample recovery. We are currently evaluating a BNP workflow in which the
primary preparative fractionation relies on standard phase ELSD coupled deactivated
silica “flash” chromatography while subsequent semi-preparative steps utilize traditional
C18 based separations; thus far, this methodology appears to provide a truly
nonequivalent, complimentary separation technique.
In similar fashion, I believe a SFC based semi-preparative approach may be most
orthogonal to the C18 based primary separations. This might also prove to be
advantageous over our standard phase techniques, as SFC potentially offers both
increased recoveries and avoids the difficulties associated with the handling and
desolvation of CHCl3. From this point in the analytical workflow HRMS data coupled
with one of the previous semi-preparative techniques should prove sufficient to separate
the initial complex hit into a number of relatively pure fractions. These high purity
fraction(s) should then be re-submitted to the bioactive assay to locate the fraction(s)
responsible for the initial hit. Once high purity fraction(s) are recovered, a number of
analytical techniques become available for the evaluation of the active chemical
compound(s).
The analysis of BNP components often relies on two very different analytical
approaches, NMR and MS. Many labs, including our own, often submit chemical hits to a
somewhat standardized NMR analysis prior to conducting any MS work. NMR based
BNP analytical techniques greatly benefit from the nondestructive nature of the NMR,
coupled with the fact any materials transferred to dueterated solvents may be easily
analyzed via MS. While NMR experiments are more contingent upon the recovery of a
sufficient sample (1-2 mg for proton, 2-5 mg for conventional 13C, 10 mg or more for
correlational studies), they offer a potential array of chemical information from simply
the number of carbons and hydrogens contained by a compound to detailed structural
information from spin correlational or NOE type experiments through a nondestructive
means.
Once the NMR work has been completed the MS work may begin, as mass
spectrometry is inherently a destructive technique, care must be taken in the sequencing
of the MS analyses. I often acquire another HRMS ESI(+) and ESI(-) full scan (Figure
26) of the active re-fractionated samples to provide a point of reference for future
analyses, as before, prospective chemical formula(s) may be generated from the high
resolution isotopic and mass defect measurements. From this point, the analytical
workflow may fork into two possible directions, one includes operating the HRMS in a
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Figure 26.
UPLC Targeted TQD-MS/MS of Control Mycolactone (765.4 m/z)
Served to Validate MS/MS Quantification Techniques
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way as to effectively overvolt the sample cone (octopole) thereby inducing nonspecific
electronic fragmentation (in this way essentially mimicking the collision cell on the
TQD), the second relies on the use of the TQD to induce kinetic fragmentation at/in its
Q2 collisional cell. (Figure 27 illustrates the kinetic induced fragmentation of the parent
mycolactone, 765 m/z, to the mycolactone core, 429 m/z, before (A) and after (B)
exposure to sunlight.) (Structure of mycolactone provided in Figure 28) Electronic and
kinetic fragmentation experiments are often complimentary in the profiles generated. The
HRMS induced fragmentation experiments may be conducted while running the
previously discussed full scans, in this way, a great deal of information may be gleaned
from a limited amount of analyte.
Traditionally the neutral losses (NL) in an unknown analytes kinetic
fragmentation spectrum have been used to provide insights into a molecule’s
fragmentation motifs and its ultimate functionalization. In the case of the TQD, these
experiments may be conducted through the utilization of NL scans or through the
creation of MRM experiments. These single or multiple reaction monitoring
(SRM,MRM) processes rely on their ability to preselect one or multiple parent
molecule(s) at the first quadrupole (Q1), subject this parent molecule to a kinetic
fragmentation event (Q2) and then analyze the resultant fragments through the use of a
final scanning quadrupole (Q3). (In a careful experiment, the kinetic potential of Q2 can
be tuned to allow for the enrichment of the mycolactone core while providing sufficient
molecular ions to discriminate between mycolactone (765 m/z) and
tetrahydroxymycolactone (747 m/z). The net effective fragmentation event can then be
ramped to provide fragments in an ascending order from the most electronically
accessible functional groups to the more shielded molecular scaffold.
In this way the TQD’s capability to precisely control the fragmentation process
provides the analytical chemist a powerful tool in the ability to back-calculate many
pieces of a molecule, as noted, the HRMS may be used to provide a similar but much less
precise fragmentation process. This serves to illustrate a theme expressed throughout NP
work; data rich MS experiments are often sample rich as well, the HRMS fragmentations
are useful as they provide much of the TQD NL/MRM data while only consuming a
fraction of the sample necessary to construct a conventional MRM experiment.
Introduction to Mycobacteria ulcerans
The causative agent of Buruli ulcer, Mycobacterium ulcerans (Mu), is the third
most common form of mycobacterial infection in humans after only TB and leprosy.109
The early stages of ulcerans infection often manifests as a small, dermal papule. Without
proper diagnosis and treatment, the bacterium slowly invades and necrotizes the
surrounding tissues through the secretion of the toxin mycolactone.110 (Figure 28). As the
affliction of Buruli ulcer is primarily concentrated in developing nations located in
tropical areas of the world111 a number of laboratories, ours included, have been
investigating the possibility of a low cost means by which to remediate the progression of
ulcerans infection.
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Figure 27.
Targeted UPLC-TQD-MS/MS of Mycolactone Subspecies 747.4 m/z
(Top) and 765.5 m/z (Bottom)
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Structure of Mycolactone (m/z=765)
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Several laboratories (including our own) have noted the instability of isolated
mycolactone.112 In collaboration with the Britton laboratory we further investigated the
effects of natural and UV light on mycolactone stability and sought to evaluate the
potential clinical relevance of such findings as a low cost approach to remediate the
effects of mycolactone toxification. While our collaborators113 were primarily concerned
with the in-vivo and in-vitro modeling of mycolactone photoablation, our laboratory aims
were to isolate sufficient quantities of mycolactone and study the effects of UV and
visible photo irradiation on the chemical composition of the toxin. The impure M.
ulcerans lipid extracts were separated and analyzed for purity following a (now
standardized) BNP workflow. Secondly, the photostability of mycolactone was assessed
via mass spectrometric tools.
In a proof of concept experiment, methanolic solutions of our internally produced
pure mycolactone were applied to transparent plates and slowly rotated until a thin film
developed. The plates were then randomly divided into two groups, light and dark. The
light group would be exposed for 30 to 120 minutes of “Memphis Sun” (atop the hospital
parking deck at 1:00 PM on cloudless days throughout May and June with an outside
temperature ranging between 78◦ and 89◦F, controls were allowed to remain outdoors
covered in ablative foil during the exposure in an attempt to differentiate thermal and
photo-induced degradation processes). The thin films would be resolvated in CH3OH and
divided for bioanalysis and MS (Figure 29) illustrates the conservation of 765 m/z to 429
m/z (indicative of mycolactone) prior to exposure to sunlight (A), the daughter peak was
lost post-exposure (B) indicating the disruption of the polyene system. The bioanalytical
technique involved treating human keratinocytes with aliquots of the light (E) and dark
(F) mycolactone samples, while kill curves remained similar; the light group required a
half-log increase in dose to achieve similar toxicity (Figure 30). In a comparison of
mycolactone toxicity between batches (Figure 31) the new mycolactone stocks
demonstrate significantly increased toxicity, illustrating the inherent instability of
mycolactone thin film archival. While the structure of mycolactone was previously
known, an effort was made to assay the analytical invasivity of our techniques due to the
light sensitive nature of the compound. There was initial concern the UV/Vis detector
might be capable of degrading the mycolactone under analysis (Figure 32), this proved to
not be a concern as mycolactone parents 755 m/z and 747 m/z were unaffected, as no
significant change in peak area was observed.
Mycolactone Conclusions and Discussion
The recent publication by Marion112 in many ways supports the findings of this
work as well as suggesting a number of potential modifications to our current
mycolactone production and storage strategies. We have successfully shown
mycolactone’s toxic potential is mediated through the exposure to sunlight. We were able
to determine indoor light was harmful, though not nearly to the extent at sunlight (as
confirmed my Marion). We determined conclusively UV/Vis flow spectrometry does not
significantly damage mycolactone, likely due to the shielding effects of the effluent. We
were also able to develop robust TQD based assays for both quantification and
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Figure 29.
765 m/z Daughter Scan Indicating the Presence of the Mycolactone
Core (429 m/z) Prior to Sunlight Exposure (A) and Post Exposure (B)
NOTE: Post exposure, the parent/daughter transition indicative of mycolactone could not
be detected.
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Figure 30.

The Effect of Mycolactone Photoablation on Human Keratinocytes

NOTE: The UV exposed mycolactone stock (F) suffers a 0.5 log reduction in toxicity as
compared to the control mycolactone (E).
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Figure 31.

The Effect of Two Mycolactone Lots on Human Keratinocytes

NOTES: Both mycolactone lots were archived as thin films demonstrating mycolactone
suffers significant detoxification while stored as a film. The time differential between
batches was 131 days.
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Figure 32.
Analysis of Mycolactone Stability via Differential Red (Top Set) and
UV (Bottom Set) Light Flow Spectroscopy of m/z 747 (Upper) and m/z 765 (Lower)
NOTE: No significant photoablation was detected in the UV/Vis flow cell exposed
samples.
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classification of mycolactone subspecies, though we were unable to detect any significant
mycolactone degradation products (Marion also failed to report any significant
mycolactone photodegradation products and instead worked to assay primarily through
spectroscopic means).
The Marion article also suggests a few improvements may be made to our
framework. As our mycolactone efforts are shared by both national and international
collaborators, the decision was made to store, assay and ship our mycolactone stocks as
thin films. The reasoning was thin films would both reduce the accidental dissemination
of highly toxic materials as well as greatly simplify the process of shipment. (The
international shipment of highly toxic liquids is an extremely laborious and expensive
process) Marion found storage as a thin film to be the least appropriate means of
mycolactone archival due to proposed dehydration effects, mycolactone was found to be
most amenable to archival in ACN at low concentrations.
While the article makes no effort to differentiate between the photoablative and
chemical processes responsible for mycolactone’s amazingly short half-life as a film, it
will be interesting to determine if variations in our production and storage processes
persists after transitioning to solution based archival.
Buruli ulcer, the human affliction associated with the mycolactone excreted by M
ulcerans as it attempts to evade the immune responses of its unwilling host, is an
affliction largely borne by developing nations in tropical regions. While our initial
laboratory efforts were simply concerned with culturing ulcerans for the production of
mycolactone as a chemical probe, a number of our collaborators sought to leverage our
knowledge in the effort to combat Buruli. The chemotherapeutic treatment for Buruli
ulcer is the combinative administration of rifampicin and streptomycin, the intramuscular
administration route and relatively short shelf-life of these drugs preclude their clinical
application in many parts of the world. As a number of early efforts to characterize
mycobacterial secretions (including our own), observed a sensitivity to light. An effort
was undertaken to evaluate sunlight’s ability to detoxify (and possible reverse)
mycolactone associated necrosis. Clinical investigations are currently being conducted by
the Britton group in Ghana and initial results appear promising.
As noted prior as, the optimal storage conditions for the archival of mycolactone
was recently published.112 Based upon these findings, our decision to store our
mycolactone stocks as thin films should be reviewed. In light of the thin film stability
studies I believe many of the variations observed through our purification and analysis
effort were likely a product of the thin film and not wholly associated with photoablative
effects, especially in the laboratory. Our next lot of ulcerans should be ready for harvest
soon and I have already revised the separation protocols to account for the findings of
Marion.
To aid in the efforts I would like to continue the evaluation of the in-vitro photomitigation of mycolactone in an attempt to decisively answer lingering questions. While
mycolactone’s unique polyene system is responsible for the majority of the compound’s
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UV absorbance (especially at longer wavelengths), no laboratory has currently been able
to identify the remaining mycolactone fragments post photoablation. While our sunlight
exposure experiments illustrated the ablative effects of sunlight on mycolactone, I was
unable to conclusively identify any ablative fragments. I now believe this experimental
shortcoming to be a function of the thin-film as opposed to the ablative or analytical
processes themselves. As Marion conclusively illustrated, even very (60 min) periods of
thin film storage resulted in a very significant reduction in the abundance of the
mycolactone. In the next iteration of our ongoing mycolactone production and archival
efforts I will implement the dilute ACN storage and processing techniques Marion found
to be so successful. The extraordinarily low UV cutoff of high purity ACN will enable
me to carry out my photoablations while preserving the resultant fragments for HRMS
analysis and elucidation.
While the previous aim seeks to determine the most suitable form of UV
irradiation for mycolactone exposure and its ablative products, I would also like to
investigate the implications of exposing Buruli ulcer to UV and visible irradiation. Initial
ulcerans infection presents as a small, seemingly insignificant, dermal papules and over
an order of weeks to months slowly develops into a necrotic ulcer with germinal
infiltration114. M ulcerans subcutaneous implications are largely based upon the
observation that many of the most severe infections are often quite painless, presumably
due to the toxin invading and destroying the deeply distributed pacinian corpuscles (nerve
terminals housed deeply in the dermis) The question to me is, as the ulcerans is able to
slowly encroach upon the human dermis, what form of irradiation would serve to
deactivate deeply distributed mycolactone while preserving the patient’s already
compromised skin? As the susceptibility of human dermal tissues to various types of
nonionizing irradiation is known, the question is how to evaluate the UV penetration of
Buruli lesion. Collaborations are currently underway to tease out the response of dermal
infection to irradiation in Ghana via surrogate in guinea pig. I believe these data in
combination with my ablation findings will aid in the effective development of low cost
phototherapies for ulcerans infection.
In this way I believe our laboratory can continue to provide high purity
mycolactone stocks to our international collaborators and in our own little way help to
curb the global affliction of Buruli ulcer.
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Experimental Methods
The experimental methods developed throughout this chapter are outlined below.
SchuS4 Lipid Methods
Total Lipid Extraction
ASL Lipid Extracts were generously provided by the Bosio laboratory.
Fractionation of Cell Wall Associated Lipids (Modified Folsh)
A solution of MeOH/0.3% Aq. NaCl(100/10) (5 mL) and Pet. Ether (2.5 mL) was
added to lipid crude and stirred at 50oC for 30 min then centrifuged to form a partition.
The organic layer was decanted and additional Pet. Ether (2.5 mL) was added to the
remaining lipid for an additional extraction. The organic layers were combined and dried
under a stream of nitrogen. A solution of (CHCl3/CH3OH/0.3% NaCl (90/100/30) (2.5
mL) was added to the lipid containing vial and again stirred, extracted and partitioned.
The organic layer was decanted and 1 mL of a solution of (CHCl3/CH3OH/0.3%NaCl
(50/100/40) was added to the lipid stirred, extracted and partitioned. The organic layer
was again removed and the extraction was repeated. The organic layers were pooled and
dried. 2.5 mL CHCl3 and 2.5 mL 0.3% Aq. NaCl were added to the remaining lipid
mixture and briefly stirred then allowed to partition. Both layers were collected and
brought to dryness under nitrogen stream.
Fatty Acid Methyl Esterification
Methanolic HCl was prepared by adding 7 drops (250 µL) of acetyl chloride to 5
mL of very dry CH3OH in the fume hood. HCl-MeOH (2 mL) was added to 2 mg of dry
crude lipid and sample stirred to allow for dissolution. The sample was allowed to react
overnight, and then dried under a stream of nitrogen. Hexane (2.5 mL) and H2O (2.5 mL)
were added to the vial to from a partition and the layers were stirred rapidly for 20
minutes. The hexane layer was removed and additional hexane (2.5 mL) was added and
stirred. The organic extracts were dried in vacuo, resuspended in CH3OH and analyzed
via GC/MS.
GC/MS FAME Analysis
GC/MS analyses were performed on an Agilent 5975c Series GC/MSD. All
samples were diluted in CH3OH prior to injection. An Agilent DB-225 (30m x 250µm x
0.25µM) silica capillary column was utilized via thermal gradient of 90◦C for 3.5 min,
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then 4◦C/min to 220◦C for 7 min for a total run time of 43 minutes. Detection was
achieved via FID and MS. MS was configured and calibrated for “high gain” mode with a
gain factor of 15, a 5 min solvent delay and was scanned over 50 – 500 m/z. The EI
source was maintained at 230◦C while the quadrupole was heated to 150◦C.
HPLC Fractionation and Analysis
All samples were dissolved in GC/MS grade CH3OH and transferred to
autosampler vials. Separations were achieved on a Phenomenex Luna 5µ C18(2) (250mm
x 10mm x 5µm) at room temperature, flowing 3.5 mL/min of H20 + 0.1% Formic acid
(A) and ACN+ 0.1% Formic Acid (B). The first 12.5 minutes were maintained at 10%
organic followed by a linear ramp to 95% organic over 45 minutes then held at high
organic for an additional 12.5 minutes resulting in a 1 hour total chromatographic elution.
All fractions were collected in glass tubes then turbovaped to dryness. The samples
flagged through UV and ELSD were reanalyzed via UPLC/MS. Fractions found to
contain lipid moieties were divided 1:10 for bioanalysis and archival respectively.
UPLC/MS Analysis
LC/MS Analyses were performed on both a Waters Acquity UPLC-TQD and a
Waters Acquity UPLC-qTOF. All dry analytes were solvated in CH3OH and filtered prior
to analysis; liquid analytes were diluted in the same and filtered. Separations were
achieved at 0.5 mL/min via a 5 minute gradient elution from 95% H2O + 0.1% Formic
Acid to 95% ACN + 0.1% Formic Acid as follows. The first 30 seconds were held at the
starting conditions then ramped to 40% organic over two minutes followed by a ramp to
95% organic an additional two minutes then followed by a 30 second stop at the 95%
organic before returning to re-equilibrate. A Waters Acquity C18 BEH 1.7µ x 50 x
3.0mm column was maintained at 40◦C through-out the elution series. Detection was
achieved via PDA and MS.
NMR Analysis
All NMR samples were solvated in 600 uL of CDCl3. 1H spectra were acquired
via a Spectrospin automated 400 MHz Bruker spectrometer, while 2D data were acquired
on a Varian Inova spectrometer operating at 600 MHz.
Flash Chromatographic Separation of Crude Lipid
Crude lipid extracts were solubilized in 1:1 CHCl3:CH3OH through the aid of
sonication. 1 g of dry chromatographic silica was added to the lipid solution and brought
to dryness via rotovap. The lipid loaded silica was transferred to a previously equilibrated
12 g Biotage HP-Sil SNAP flash chromatographic cartridge. Elution was achieved via a
gradient separation from CHCl3 to 3:1 CHCl3: CH3OH over 15 column volumes at a flow
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rate of 12 mL/min. Detection was achieved via UV absorbance at 220 and 254 nm. All
fractions were collected in glass tubes and were brought to dryness via turbovap.
Mycolactone Methods
Isolation of Mycolactone from Ulcerans
M. ulcerans was grown in solid 7H11 plates for 14-16 weeks. Colonies were
manually selected and transferred into a PBS solution where they were harvested by
centrifugation and again washed with PBS. All PBS was then removed and 5x
weight/volume of 5:1 EtOH:H2O was added and extracted for one hour at 37◦C. The
solution was then clarified via centrifugation and the supernatant decanted. The
extraction process was repeated until the EtOH solution no longer retained a yellow
coloration (2-3x). The extracts were brought to dryness via rotovap. The dry materials
were resolvated in acetone with the aid of sonication and filtered to remove remaining
cellular debris then again brought to dryness via rotovap
Sunlight Induced Photodetoxification of Mycolactone
1 mL of mycolactone solution (500 µL/mL) was applied to transparent plastic
plates. The plates were slowly rotated to allow the formation of a thin film and randomly
assigned to two groups. The control group was carefully wrapped in parafilm then
aluminum foil. The exposure group was covered with a transparent quartz slides, both
sets of samples were carefully transported outdoors on a sunny day near 1 PM and
exposed to sunlight for periods of 30 minutes to 2 hours. The films were then removed
via CH3OH and analyzed via GC/MS.
HPLC Fractionation and Analysis
All samples were dissolved CH3OH. Separations were achieved on a Phenomenex
Luna 5µ C18(2) (250mm x 10mm x 5µm) at room temperature, flowing 3.5 mL/min of
H20 + 0.1% Formic acid (A) and ACN+ 0.1% Formic Acid (B). The first 12.5 minutes
were maintained at 10% organic followed by a linear ramp to 95% organic over 45
minutes then held at high organic for an additional 12.5 minutes resulting in a 1 hour total
chromatographic elution. All fractions were collected in glass tubes then were turbovaped
to dryness. The samples flagged through UV and ELSD were reanalyzed via UPLC/MS.
Fractions found to contain mycolactone were selected for archival.
Flash Chromatographic Separation of Crude Lipid
Crude lipid extracts were solubilized in 1:1 CHCl3: CH3OH through the aid of
sonication. 1 g of dry chromatographic silica was added to the lipid solution and brought
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to dryness via rotovap. The lipid loaded silica was transferred to a previously equilibrated
12 g Biotage HP-Sil SNAP flash chromatographic cartridge. Elution was achieved via a
gradient separation from CHCl3 to 3:1 CHCl3: CH3OH over 15 column volumes at a flow
rate of 12 mL/min. Detection was achieved via UV absorbance at 320 and 360 nm. All
fractions were collected in glass tubes and were brought to dryness via turbovap.
LC/MS Analysis
LC/MS Analyses were performed on both a Waters Acquity UPLC-TQD and a
Waters Acquity UPLC-qTOF. All dry analytes were solvated in CH3OH and filtered prior
to analysis; liquid analytes were diluted in the same and filtered. Separations were
achieved at 0.5 mL/min via a 5 minute gradient elution from 95% H2O + 0.1% Formic
Acid to 95% ACN + 0.1% Formic Acid as follows. The first 30 seconds were held at the
starting conditions then ramped to 40% organic over two minutes followed by a ramp to
95% organic an additional two minutes then followed by a 30 second stop at the 95%
organic before returning to re-equilibrate. A Waters Acquity C18 BEH 1.7µ x 50 x
3.0mm column was maintained at 40◦C through-out the elution series. Detection was
achieved via PDA and MS.
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CHAPTER 3.

HRMS BASED METABOLIC PROFILING OF COMPOUNDS
FOR THE TREATMENT OF TUBERCULOSIS
Introduction to Drug Resistance

Drug resistance is a general term used to indicate a chemotherapeutic agents loss
of efficacy for a particular indication. Bacterial resistance occurs when a bacterial
pathogen is able to survive exposure to a chemotherapeutic agent to which it previously
was susceptible. Numerous bacterial resistance mechanisms are known to exist arising
from mutation, natural selection and external evolutionary stresses115 (i.e., exposure to
antimicrobial agents). It is well documented that natural product based antimicrobial
agents as well as the bacterial genes now known to confer resistance have existed since
antiquity.116 Unfortunately, the rampant overuse of antibiotics in both human and
domesticated livestock populations as seen over the last half century has led to a new and
disturbing phenomenon of greatly increased incidences of drug resistant pathogens in the
clinic.117
This overwhelming increase in the drug related selective pressures placed upon
pathogenic bacteria has led to the development of highly virulent bacterium, resistant to
many of the most common anti-infective compounds on which modern human society
has come to depend.118 Numerous efforts to decrease the antimicrobial burden on animal
food-stocks are currently underway, while most prescribers have voluntarily enlisted in
antibiotic stewardship programs.119 While there is a near universal consensus the efforts
to limit the selective pressures placed upon bacteria are both timely and necessary. The
majority of the front-line antibiotics currently in clinical use have continued to see
dramatic reductions in efficacy120 and there is a major concern that antibiotic stewardship
efforts are being undermined by poor drug administration practices in developing
nations.121
It is becoming increasingly clear that antibiotic stewardship alone is not sufficient
to curb the ever increasing rate of bacterial resistance.122 New antimicrobial
chemotherapeutic agents are desperately needed to replace our aging antibacterial
arsenal. Unfortunately, the 1980-1990’s witnessed a steep decline in both the monetary
investment and productivity of many large-scale pharmaceutical companies as numerous
anti-infective programs were shuttered in pursuit of therapies offering higher returns.123
While this decade has witnessed something of a renewed interest in the commercial
investigation of antibiotic small molecules, the battle currently appears to be favoring the
pathogenic organisms over their human hosts.
New Compounds Needed to Combat Antimicrobial Resistance
As ever increasing rates of resistance continue to limit the clinical efficacy of
existing antimicrobial compounds, the need for new drugs becomes all the more urgent.
As viewed through the lens of bacterial resistance another aspect of classical antibiotic
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development becomes troubling. While many antibiotic agents exist on the market today,
the vast majority of them exist as only minor modifications to previously approved drugs.
This limited diversity in the anti-infective drug space makes not only resistance but crossresistance a persistent threat.124 Over 70% of the antibiotic agents approved by the FDA
since 1982 have been modifications of only two chemotherapeutic classes, quinolones
and beta-lactams.125 Furthermore, the golden age of antibiotic research (1940-1970)
witnessed only 14 classes of novel antimicrobial scaffolds approved for use in humans.126
Only five truly novel scaffolds have been approved since; mupirocin, pleuromutilins,
lipopeptides, oxazolidinones and glycylcyclins. The question now is how does a scientist
go about discovering a previously unknown chemical scaffold which may be
synthetically manipulated into a chemotherapeutic agent?
The answer is both complex and multifaceted; some have chosen to screen large
bio-diverse libraries, others have relied on structure-based design while still others have
chosen to utilize combinatorial approaches.127 At this time there appears to be no truly
right or wrong answer. One critical deficiency in many of the current antimicrobial drug
development pipelines is the early preclinical investigation of an agent’s bacterial
metabolic stability. Preclinical MS/MS screening provides scientists the ability to
preselect drug candidates exhibiting excellent metabolic stability in the host and with
respect to degrading enzymes found in some bacteria. Work in this chapter seeks to
utilize high resolution mass spectrometry as a tool to investigate how both bacteria and
the human body modify and eventually eliminate therapeutic agents modeled upon both
spectinomycin and nitrofurantoin, and seeks to apply this knowledge towards the
eventual synthesis of novel synthetic scaffolds.
Introduction to Antitubercular Chemotherapeutic Agents
A number of commercially available antibiotics are currently utilized in the
treatment of tuberculosis worldwide. Antitubercular drugs are commonly subdivided into
first-line and second-line agents, with the first-line agents generally conferring fewer offtarget (side) effects.128 The first-line class is composed of rifampin, isoniazid,
pyrazinamide, ethambutol and streptomycin.129 The second-line agents generally include
kanamycin, cycloserine, ethionamide, capreomycin and para-aminosalicyclic acid.130
While individual therapies of first and second-line agents may be capable of inhibiting
the proliferation of tuberculosis, TB mono-therapies have been largely discontinued due
to the rapid conference of drug resistance.131 The current CDC recommendation for TB
infection is RIPE132 (rifampin, isoniazid, pyrazinamide, ethambutol) coadministration for
two months followed by an additional 4-6 months of rifampicin and isoniazid. In cases of
suspected multidrug resistant tuberculosis (MDR-Tb) RIPE therapy is recommended for
18-24 months.133 While RIPE therapy confers a near 95% cure rate when administered as
directed, the complicated dosage form (up to 20 pills daily) often results in poor patient
compliance and subsequent manifestation of MDR-TB.134 New TB drugs are desperately
needed both to replace chemotherapies relegated through resistance as well as to offer
increased patient compliance through reduced dosage frequency. Encouragingly there are
a number of new TB chemotherapies currently in clinical trials, including; LL-3858, PA-
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824, OPC-67683 and KRM-1648(Rifalzil), which soon may afford adjunctive
administration to RIPE, potentially reducing the duration of RIPE therapy and associated
patient non-compliance.
Introduction to M. tuberculosis Pathogenicity
The wide spread use of antitubercular agents coupled with poor patient
compliance and HIV co-infection has led to a drastic increase in the instance of drug
resistant infections seen in the clinic over the past twenty years.135 While numerous “best
practice” strategies seek to limit the evolutionary pressure collectively placed upon
pathogenic bacteria such as tuberculosis, new antitubercular compounds will be required
to effectively combat infections in the near future.136 The key to the development of any
new antibacterial agent is an advanced understanding of the mammalian immune system
and of the strategies tuberculosis employs to evade it. The human immune system and
infectious tuberculosis bacteria have co-evolved together, with each organism seeking to
develop more effective countermeasures against the other. On the front line of this everpresent conflict are the phagocytes seeking to envelop and destroy evading
microorganisms and obligate human pathogens such as M. tuberculosis which seek to
corrupt these biochemical machines for their own gain.137
Phagocytes are white blood cells tasked with internalizing and destroying
invading organisms and are often loosely grouped based upon their affinity for
phagocytosis. The most aggressive or professional phagocytes (macrophages, monocytes,
neutrophils dendritic and mast cells) are specially equipped to ingest and destroy large
cells including bacteria.138 Phagocytes are capable of detecting pathogens both indirectly
through opsonins (commonly IgG) and directly through the use specific receptors presensitized to antigens expressed upon bacterial cell walls. Once an invading bacterium
has trigger the phagocyte, a phagosome is formed through the remodeling of actin aided
by phosphoinositides and myosin X.139
The ultimate goal of this remodeling is to move the bacterium from a free
environment to a completely encapsulated compartment of the phagocyte in a process
known as phagosome sealing. Once the phagosome is complete the process of maturation
may begin, in the maturation stage a number of lysosomes are fused with the newly
formed phagosome and the lumen is slowly acidified.140
As the early phagosomal lumen continues to acidify, additional biochemical
processes are responsible for beginning to confer antibacterial properties to the phagocyte
through the activation of numerous GTPases and SNARE proteins. Once the pH falls
below about 6.0, proton-pumping V-ATPases are recruited to further drive the luminal
acidification in this so called late phagosome.141 The late phagosome continues to be
enriched through the incorporation of proteases and liposomal proteins, ultimately
resulting in the creation of phagolysosome. An organelle specifically created for its
devastating antimicrobial properties. Phagolysosomes, rely on a number of powerful
weapons to completely destroy the encapsulated microorganism; the foremost being a
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highly acidic phagosome (pH 4.0 - 5.0) as well as antimicrobial peptides, proteases, iron
scavengers (such as lactoferrin) and NADPH family oxidases.142
While the immune system has evolved powerful defenses against most bacteria,
some bacterial pathogens, including M. tuberculosis, have developed advanced strategies
seeking to subvert or attenuate a normal immune response. Though numerous microbial
organisms have devised systems to elude the immune system, there exist a small number
of “professional” pathogens capable of not only surviving inside of the phagosome but
thriving there.
Mtb is one of the few successful intracellular bacterial pathogens with the ability
to avoid many of the destructive mechanisms of the phagocytic compartment, primarily
by preventing the phagosome from fully maturing. While the pH of the native
phagolysosome often reaches 4.5, the phagosomal acidification of Mtb infected cells
stalls well before they reach toxic levels143 (pH 6.4). While there exists some debate as to
how the bacterium is able to effect maturation, a number of cell wall glycolipids seem to
have been decisively implicated in the process.144 In concert with Mtb’s ability deceive
the phagosome, the bacterium is also able to enter a number of replicative states to further
its ability to survive in a potentially hostile environment. Once the bacterium has
successfully evaded the body’s initial defensive efforts it begins to proliferate rapidly.
This period of rapid proliferation, primarily concentrated to the alveolar macrophages,
continues until the host is able to mount an acquired immune response.145
At this point in the infection the bacterial count begins to plateau, many of the
initial overt signs of the disease fade and the pathogen enters a stage of immune mediated
control.146 While the exact cause of Mtb’s perceived stasis remains unknown, many
believe hypoxia remains primarily responsible for control of bacterial growth in the
chronic stages of persistent infection.147
The immunological responses mounted against the invasion of M. tuberculosis
and the pathways the pathogen employs to subvert them are complex. Mtb has evolved
the ability to evade the early immune defenses targeted against it, as well as to package
itself into a defensive granuloma once the body is capable of mounting a significant
response.148 These traits have enabled Mtb to become a persistent pathogen without the
reliance upon an animal reservoir, and have greatly complicated the treatment of
persistent infection. However, it is hoped that a greater understanding of the human
immune system and the mechanisms Mtb uses to usurp it will prove instrumental in the
development of new chemotherapeutic agents against this enduring threat. To this end,
this work seeks to provide a greater understanding of the host/pathogen symbiosis in two
important ways. First, through the application of HRMS tools to investigate the small
molecule bacterial metabolites (lipids and mycolactone) responsible for perturbing the
innate immune response and secondly, to probe the chemical processes that serve to
influence the metabolism of anti-infective chemotherapies.
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An Overview of MS Metabolic Profiling
The initial discovery and subsequent testing of any new therapeutic agent is an
extremely expensive and time-consuming venture. Current estimates place the cost of
deploying a novel therapeutic compound at around one billion dollars with an average
time to market of just over twelve years.149 To remain competitive, any serious venture
must have some framework on which to evaluate the many hundreds if not thousands of
hits often generated by modern cell based screening of large chemical libraries. Add to
this cost the troubling high rate of attrition, over 70% off all new chemical entities
(NCEs) ultimately fail and the potential impact to both the pharmaceutical industry and
academic researcher is severe.150 Beyond these initial expenses, one must also consider
the potential implications to the patient, as adverse drug reactions (ADR) due to
unfavorable drug metabolism and pharmacokinetics (DMPK) is a leading cause of NCE
withdrawal.
From this flood of data researchers must ultimately select a small number of lead
compounds to undergo a battery of costly test aimed at evaluating a potential NCE’s
efficacy as well as its’ toxicological profile. A number of relatively new analytical
techniques have proven themselves indispensable in their ability to rapidly evaluate
NCEs throughout the development and testing process. Nobilis states,151 high throughput
liquid chromatography tandem mass spectrometric (LC-MS/MS) techniques coupled with
medium throughput, high information content, liquid chromatography nuclear magnetic
resonance spectroscopy (LC-NMR) have proven invaluable in their ability to quickly
evaluate NCEs. LC-MSn techniques have proven applications throughout the evaluation
of chemical leads. From early hit identification and sample quantification, through
traditional adsorption-distribution-metabolism-excretion (ADME) workflows and finally
onto the prediction of ADRs through the investigation of potentially reactive chemical
species152 (RCSs).
This work will primarily focus on the application of LC-MSn techniques to the
identification of metabolites as RCSs and the pharmacokinetic (PK) profiling of drug
metabolism. Over countless years the human body has evolved defenses against the
incursion of foreign or exogenous compounds, these xenobiotic agents are systematically
functionalized through a series of chemical reactions leading to the increase of a toxins
hydrophilicity and ultimately to its excretion.153 These biochemical reactions may be
further subdivide into two metabolic phases; phase I, cytochrome P450 mediated
biotransformations often seeking to insert a nucleophile (commonly hydroxyl) decreasing
a compound’s lipophobicity and inserting a site for the ultimate phase II conjugation and
excretion of a drug through the urine.154 Given these transformations usually occur in a
predictable manner and aided by advances in synthetic physical property prediction
algorithms, scientists now have the ability to generate metabolic profiles of a lead
therapeutic compound in advance of costly clinical trials. These projected PK profiles
coupled with synthetic metrics of solubility, distribution, polar-surface-area (PSA) etc.,
may then be used in selecting chemical leads to continue through the development
pipeline.155
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As noted earlier, the modern PK framework must be capable of handling the
heavy workflows endemic to drug discovery laboratories, as such, tasks must be logically
ordered so that rapid, automated (information poor) analysis may be used to guide more
time consuming, information rich, steps. The initial classification of most NCE
metabolites will often be conducted with the aid of the TQD, as a number of different
experiments may be conducted in a highly efficient fashion. One of the most common
experiments156 involves the operation of a single quadrupole (Q1) in the TQD. This
single scan acquisition is used to rapidly provide data such as; ionization efficiency (the
ability to detect positively or negatively charged molecular ions), nominal mass
difference (mass of parent +/- mass of analyte) and qualitative nitrogen content according
to the “nitrogen rule”. The so called nitrogen rule states that organic compounds
containing exclusively hydrogen, carbon, nitrogen, oxygen, silicon, phosphorus, sulfur,
and the halogens have either 1) an odd nominal mass that indicates an odd number of
nitrogen atoms are present or 2) an even nominal mass that indicates an even number of
nitrogen atoms are present in the molecular ion.157
This easily obtainable information is then used to target more advanced TQD
experiments, these so called precursor-ion and product-ion scans rely on the systematic
destruction of incoming molecular ions in the TDQ’s collisional cell to create
characteristic fragmentation patterns. In this way, these distinct molecular fingerprints
may be used to identify various metabolic pathways; as in the neutral loss of 176 m/z (the
fingerprint of glucuronidation) or the precursor loss of 80 m/z (indicative of sulfation).
The data generated from scanning and collision induced analysis may then be used in the
design of multiple reaction monitoring (MRM) assays, in which the fragmentation
patterns of known metabolites are preselected, effectively eliminating background
noise158. In this way MRM experiments can prove to be extremely valuable in the
quantification of metabolic products, while a truly powerful technique, MRM
experiments usually reside at the end of the TQD based workflow as the design of a
meaningful MRM experiment can prove very time consuming. See Table of
Characteristic Metabolic Transformations (Appendix A and Tables 3 and 4).
While the TQD remains the workhorse of most any metabolomics laboratory,
recent advances in bench-top high resolution mass spectrometers (HRMS) have allowed
many institutions access to the world of accurate mass spectrometry.159 HRMS data has
proven extremely valuable for the predication of proposed chemical formula based upon
a compounds isotopic elemental abundance or mass defect. Trace level metabolic
pathways can now be rapidly elucidated based upon the mass defect observed between
parent and metabolized products aided by the complimentary fragment data provided by
TQD analysis.
HRMS Stability Analysis of Spectinomycin Derivatives
Our laboratory has an ongoing effort to synthesis new spectinomycin analogs in
an effort to overcome the primarily, efflux pump mediated, resistance that precludes the
parent compound from widespread clinical compatibility. Three of the lead compounds in
our spectinomycin derivative series are Lee-1329 (Figure 33), Lee-1544 (Figure 34) and
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Structure of Lee-1544
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Lee-1599 (Figure 35). The identification of these metabolites was sought to guide further
medicinal chemistry efforts and evaluate potential metabolite related toxicities and to
study the potential for drug interactions. Using a careful structural analysis of these drugs
a number of theoretical metabolic sites and products were proposed as illustrated for Lee1329 (Figure 36) and Lee-1544 (Figure 37). Based upon the initial findings HRMS
experiments were designed to determine the exact nature of metabolic products both invivo and in-vitro. Initial microsomal stability studies indicated Lee-1329 and Lee-1544
were susceptible limited metabolic degradation. Preliminary rat liver microsomal phase-II
metabolism stability data indicated Lee 1329, 1544 and 1599 did not serve as substrates
for glucuronide conjugation nor were they significantly degraded through sulfoconjugation. However, primary screens indicated Lee 1544 was significantly metabolized
phase-II glutathione conjugation.160,161
MassLynx and HRMS Analysis of Microsomal Stability
Preliminary data indicated both 1329 and 1544 were poor substrates for
elimination via glucuronidation (Figure 38) or sulfo-conjugation (Figure 39) and these
results were confirmed upon HRMS Analysis. The further investigation of GSH
conjugation products was, however, more involved (Figure 40). The more nonpolar 1544
will be utilized to illustrate the applications of HRMS metabolic profiling. The first minor
departure from the initial finding is that a global comparison of the parent drug across all
microsomal samples indicated that while the concentration of parent drug was reduced in
the GSH plates, 1544 was more stable than initially expected. Upon data analysis an
extracted ion integration of the parent 1544 (487.2 m/z) revealed that 91-93% of the
parent 1544 remained unchanged depending on the particular extract analyzed.
Upon background subtraction and analysis the GSH analytes were found to
contain two interesting highly polar compounds apparently related to the parent 1544
(487.2165 m/z, 1.43 min). The GSH compounds contained two interesting co-eluting
peaks at 0.51 (308.1049 m/z) and 0.63 (613.2486 m/z) minutes, respectively (Figures 41
and 42).
As numerous pathways exist to further detoxify GSH conjugation products the
lack of the prototypical Δ 306 m/z has been previously reported, especially in hydrophilic
halogenated substrates.162 Figure 43 illustrates a free GSH moiety while Figure 44 is
the observed GSH-1544 Conjugation Product.
MassLynx and HRMS Urinalysis of Lee Compounds
Upon completion of the in-vivo studies, the program was advanced in an effort to
elucidate the metabolic fate of 1544 in rats. Sprague Dawley rats were catheterized and
dosed the investigational spectinomides intravenously at 10 mg/kg body weight. The
urine was collected on six hour intervals for the first 12 hours, then on 12 hour intervals
for an additional 60 hours. The crude urine was processed via centrifugation and CH3OH
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Figure 38.
Preliminary Phase 2 Glucuronide Conjugation of Lee Compounds
and Control in Rat Liver S9 Microsomes
NOTE: All Lee compounds appear highly stable.
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Figure 39.
Preliminary Phase 2 Sulfo-Conjugation of Lee Compounds and
Control in Rat Liver S9 Microsomes
NOTE: All Lee compounds appear highly stable.
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Figure 40.
Preliminary Phase 2 Glutathione Conjugation of Lee Compounds and
Control in Rat Liver S9 Microsomes
NOTE: Lee compounds 1329 and 1599 appear highly stable, while Lee 1544 suffered
some metabolism.
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Figure 41.
Extracted Ion Spectra of Lee 1544 Remains Unchanged at the
Conclusion of Microsomal Incubation, Indicating 1544 Is Significantly More Stable
than Initially Predicted
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Figure 42.

Comparison of Microsomal HRMS Extracted TIC for Lee 1544
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Structure of Protonated 1544 GSH Conjugation Product
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protein precipitation. Recent modifications in our methodology have allowed the
detection of the 1544 parent out to the 60 hour timepoint. (Figure 45).
HRMS Stability Analysis Conclusions and Discussion
We have been able to identify free glutathione as well as a previously unknown
1544 GSH-conjugation product aided by the high sensitivity of the qTOF. Recent
enhancements to chromatographic methodology have enabled us to track the 1544 parent
in rat urine over two days after a single dose of investigational compound is
administered. The sensitivity of the HRMS has not only enabled the discovery of new
metabolites but has provided the ability to detect extremely small concentrations of
analyte in complex matrices. In spite of this, I was unable to detect the 1544 GSH
conjugation product identified from in-vitro analysis in the in-vivo studies. However, I do
not believe this to be a fault of the analytical technique, as GSH conjugation products are
known to be rapidly degraded in rodent surrogates.
Unfortunately, the instruments high sensitivity comes at a relatively high cost. In
sensitivity mode the accurate mass information is simply not ‘accurate’ enough for
effective mass defect tracking or the prediction of isotopic chemical formula. The
relatively low single dose of drug complex with the incredibly complex background of
urine in many ways limit the application of advanced MS techniques in the same way as
the highly polar molecules limit the application of conventional chromatographic tools.
For this reason many leading PK laboratories employ a new generation of TQDMS instrumentation for the investigation of phase-II metabolic conjugation through
neutral loss and precursor scanning, unfortunately the TQD we have available in our
department simply does not have the sensitivity or dynamic range to facilitate such
experimentation.
In this section I wish to discuss the general lessons learned from my graduate
work which have largely focused around the use of mass spectroscopy to study drug
metabolites and bacterial natural products. In generating this thesis I have been advised a
dissertation is meant to contain a succinct work and does not have to contain everything
you have accomplished in graduate school. While at St. Jude I have generated countless
HRMS metabolic profiles for investigational (PD30, Nitazol, FL1) new agents and
marketed drugs alike. Cetrorelix, a new compound, has been included in this work
(Appendix C) to demonstrate the principles of PK profiling.. While I believe our HRMS
PK techniques have seen considerable successes, in many ways our PK workflow is
restricted by the lack of a high sensitivity TQD. As previously mentioned most PK
laboratories now utilize the improved dynamic range and sensitivity of modern TDQ’s to
perform precursor and neutral loss scanning experiments for the characterization of low
level metabolites. Unfortunately our current TQD simply does not have the sensitivity or
dynamic range to facilitate the investigation of very dilute analytes. I believe our
laboratories’ efforts would receive great benefit through the acquisition of a more
appropriate TQD-MS instrumentation.
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Figure 45.

1544 Urinalysis TIC and Extract Ion Spectra

NOTE: The parent 1544 can be easily traced past the sixty hour time point
demonstrating the sensitivity of the HRMS technique.
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A number of instrument manufactures currently offer TQD-MS systems designed
for the quantification of extremely dilute analytes. I believe the most appropriate
instrument for the analysis of both dilute pharmacokinetic samples as well as complex
bacterial natural products lies in an AB SCIEX 6500. This modern TQD would afford a
near 20 fold increase in dynamic range and sensitivity compared to our current Waters
TQD. Additionally, the 6500 is the first triple quadrupole to offer both ion mobility drive
(SelexION) and a pulsed ion source in a single instrument. The application of ion
mobility technology enables the interrogation of extremely complex samples (Ft lipid)
while the pulsed ion source serves to significantly reduce background noise and further
increase sensitivity.
Using a new generation of powerful mass spectrometers the field of preclinical
pharmacokinetics (ADME) has witnessed intense growth over the past ten years,163 with
our hospital (SJCRH) recently forming a preclinical PK core for the optimization of
internally synthesized chemotherapeutic agents. I believe the continued application of
mass spectrometric techniques in this area will continue to offer a number of benefits
both scientifically and financially.
To the scientist, early ADME data offer an opportunity to rapidly evaluate a
potential therapeutic agent’s metabolic stability, biological distribution and route of
elimination as well as simple metrics such as plasma protein binding and solubility. The
availability of this type of information at the laboratory or department level allows the
individual chemist to rapidly evaluate synthetic molecule and propose new chemical
iterations in a rapid succession. This information also serves to provide insights into the
potential chemical reactivity of prostatic groups and the production of highly reactive
intermediates (toxicity). While independently these types of analysis are in no way new,
the ability to rapidly evaluate synthetic chemotherapies in-house potentially allows each
scaffold enumeration to occur in a matter of weeks as opposed to the months or years
required through more traditional lot based synthetic and analytical models.
From a financial standpoint, the in laboratory analysis of preclinical ADME allow
unfavorable compounds to be excluded from the development pipeline much more
rapidly than through traditional techniques. This pipeline annotation allows the scientist
to evaluate the ADME implications of a particular scaffold or prosthetic modification
prior to selecting the candidates for further enumeration This ability to further develop
only the “most fit” compounds from a particular series not only yields dividends but
helps to prohibit the submission of unfit compounds to the extremely costly and failure
prone (previously outlined) NCE evaluation workflow.
Introduction to Antitubercular Nitrofurans
It is currently held RIPE TB therapy must be maintained for very long durations
to effectively combat latent and/or slow-growing populations of bacteria.164 These
subpopulations of Tb infection are believed to be innately resistant to current front-line
antibiotics due to a reduction in bacterial metabolism.165 Furthermore, these latent
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populations often manifest as granulomas, further encapsulating the bacterium in an
acidic, hypoxic (microaerophilic) environment,166 an environment in which nitroaromatic
antibiotics ,including clinical candidate PA824, are thought to be one of the few classes
of drug able to act. Our laboratories have been developing an analogous series of
nitrofuran isoxazolines designed to effectively target latent tuberculosis, which has also
exhibited significant efficacy against oxygen starved (NRPII) tuberculosis in-vivo.167
Through the specific targeting of these metabolically hindered TB subpopulations new
agents may soon be administered as an adjunct therapy to RIPE, thereby reducing the
duration of TB chemotherapy and the potential for patient non-compliance.
An Overview of Activity Based Profiling (Click)
While the principals of activity tagging via cycloaddition of an analytical probe
have been well established for the investigation and elucidation of large molecules; our
laboratory sought to apply a derivative of the Cravatt technique to the investigation of
small molecule metabolites in those of nitrofuran antibiotics. The following will briefly
discuss the Cravatt Click methodology as applied to the investigation of a large molecule
(serine hydrolase) for the purpose of introducing the highly validated workflows we now
employ for the investigation of bacterial metabolites. It should also be noted the biotinstreptavatin analytical techniques first developed in concert with Jessani served as the
foundation for the analytical processes utilized in the investigation of our “heavy”
metabolic products.
Historically, proteomic techniques have sought to accurately measure the
abundance of a target protein, and unfortunately, have only been able to provide an
indirect metric of a proteins absolute activity. Similarly, many genomic tools have also
been based upon the assumption that the abundance and activity of an enzyme remains
directly proportional over time. Many believe this key linearity assumption
fundamentally limits the ultimate utility of conventional proteomic and genomic tools.168
In an attempt to overcome these limitations, Cravatt et al., sought to combine both
chemical and biological tools into a multidisciplinary, Activity Based Protein Profiling
(ABPP) approach “that utilizes active site-directed probes to profile the functional state
of enzymes in whole proteomes.”169
ABPP relies on the use of a synthetically derived chemical probe which interacts
to label the active enzyme but disregards inactive or chemically inhibited isoforms,
thereby directly reporting only the active fraction of a given protein complex. This metric
of direct activity has proven greatly beneficial in the elucidation of major post
translational processes directly responsible for the regulation of enzyme function.
Since the introduction of this new approach a number of highly specific chemical probes
have been synthesized for use in a highly diverse set of clinically relevant targets.170
In 2005, Jessani and Cravatt, reported the successful application of ABPP in the
identification of enzymes upregulated in invasive human cancer cell lines of differing
tumor types, including urokinase (previously recognized in tumorigenesis) and the novel,
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integral membrane serine hydrolase, KIAA1363.171 The experiment consisted of
essentially two parts; the first involved the introduction of biotinylated-rhodaminefluorophphosphonate (FP) tags to prefractionated samples of human cancer cell line
proteomes. The fractions were allowed to react at room temperature for one hour, and
then treated with PNGaseF to deglycosylate the proteomes, reactions were quenched, run
on SDS/PAGE and visualized via a fluorescence scanner. Absolute band intensities were
calculated and integrated for the labeled proteins, enzyme activities were then tabulated
by comparing multiple independently labeled reactions, data points were then averaged to
report enzyme activities across each particular cell line.172
Secondly, following gel-based separation; the labeled analytes were isolated using
standard biotin-streptavatin based solid phase affinity purification techniques. The
enriched FP-labeled proteins were again separated via SDS/PAGE, with the resultant
bands mechanically harvested and subjected to trypsin digestion. The peptidic fragments
were then fixed using 2,5-dihydroxybenzoic acid (DHB) and analyzed using standard
MALDI-TOF based analytical techniques, the resultant data was then cross-referenced
against known FP-labeled and native proteins via public protein databases.173
In an attempt to provide a consolidated reporting of enzyme activities profiles, the
author conducted a cluster analysis seeking to visualize the serine hydrolase
concentrations averaged against a cell line known to be highly active, this relativized data
was then subjected to a hierarchical clustering algorithm with the average linkage the
determinate of similarity. As noted earlier, the novel membrane associated serine
hydrolase KIAA1363 was found to be consistently upregulated and has been proposed by
the authors to represent a novel marker for cancer cell invasiveness. In addition to the
identification of KIAA1363 the authors go on to report a number of interesting pathways
mediated via post translational modifications, namely in cathespin A and urokinase,
which would have been near impossible to discern without the use of ABPP
methodology.174
Rational for Click Metabolic Pulldown
To date, a Scifinder search of “Activity Based Protein Profiling” yields over 325
discrete hits. This volume of work conclusively illustrates the usefulness of ABPP in the
characterization of human cancers, as well as demonstrates the potential utility of activity
mediated cellular tagging. Following these ideas, and after careful consideration of the
relevant literature, our lab sot to employ similar tagging and gel based separation
techniques to investigate the method of action (MOA) and metabolic fate of nitrofuran
based antimicrobial agents.
Nitroaromatic drugs, in particular nitroimidazoles PA824 and OPC67638 are
showing great promise as antitubercular agents in current clinical trials175. For this class
reductive metabolic activation is known to be required for action. In 2008, Singh et al176.,
reported on nitrous oxide (NO) formation (Figure 46) and release by PA-824 (a bicyclic
nitroimidazole) which shares a similar structure-activity relationship (SAR) to our
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Proposed Imidazole Metabolic Pathway Illustrating the Generation
and Release of Highly Activated NO Species
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nitrofuran analogs presumably as they reductively activated by similar pathways.
However it is thought that the ultimate target of nitroimidazole and nitrofuran drugs is
different, as the nitrofuran activated species is more stable and likely to form adducts.
Coupled with the knowledge of ABPP principles, we set out to investigate the metabolic
fate of our novel antimicrobial compounds as the nitrofuran metabolic process is as yet
unknown in M. tuberculosis.
The structure of traditional nitrofuran antimicrobial agents is illustrated for
reference in Figure 47 (Nitrofurantoin) and representative antitubercular nitrofuran
developed by our laboratory (Figure 48). In preliminary studies we observed that our
nitrofurans did not release NO as observed in the Singh study with PA824 (Figure 49)
which lead us to hypothesize that they act through radical addition rather than NO
generation. To support this hypothesis we sought an indirect approach to study nitrofuran
activation and targeting, in much the same way as Cravatt, has sought to supplement
indirect proteomic click tagging techniques.
Having theorized nitrofuran compounds might undergo a metabolic fate different
to that of Singh’s nitroimidazoles, and drawing inspiration from another method often
championed by the Cravatt lab, we designed an experiment based upon the incorporation
of a so called “click” tag170 (Figure 50). This cycloaddition technique, popularized by
Sharpless,177 is somewhat unique in its’ ability to couple an azide to alkyne in highly
aqueous environments. To this end, we synthesized a number of our nitrofuran
antimicrobial compounds to contain a solvent accessible alkyne. The probe molecules
were designed in a way as to position the cycloaddition site away from bounds though
necessary for protein-ligand interactions. All cycloaddition probes were tested for
preservation of MIC, the six most active compounds were selected for continued
investigation (Figure 51 and Table 1). We believed the incorporation of these high
affinity tags would allow the investigation of targets of nitrofuran metabolic activation
and ultimately mycobacterial inhibition. For simplicities sake, we termed the two
potential targets the “light” pathway and the “heavy” pathway based on the molecular
weight of the products. In the light fraction, small molecule conjugates and activated
nitrofuran decomposition products were selected for via the click inclusion of a high
activity fluorescence tag to allow detection of the product conjugates at low levels. In
particular, one proposed conjugation was mycothiol, which is the mycobacterial analog
of glutathione, which function is thought to as a buffer in the mycobacterial cell against
electrophilic species.
In the heavy fractions we sought to recover probe-protein conjugates, to see if
there was a dominant proteinacous target for this inhibitor class. In both cases the small
and biological alkyne “click” tag should allow the probes to interact with the nitrofuran
activating enzymes and find their ultimate cellular target without blocking the binding
state of the drugs as would be the case with larger covalently tagged probes. The click
tags can then be conjugated to a fluorophore for the light fraction or biotin for the heavy
fraction to allow streptavidin capture and subsequent protein analysis. From this point the
methodology was straight forward; the probe was incubated in the presence of M. Bovis
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Table 1.

MICs of Acetylene Tagged Nitrofurans against Gram (+VE) Bacteria
Click Probe

B.
anthracis
sterne

E. faecalis

S. aureus
ATCC29213
(MSSA)

S.
pyogenes

S.
pneumoniae

B.
subtilis

MRSA
NRS70

Lee 1397
Lee 1521
Lee 1534
Lee 1575
Lee 1595
Lee 1618

>200
>200
>200
>200
>200
>200

50
100
200
200
200
>200

6.25
3.13
12.5
12.5
6.25
100

25
12.5
50
50
12.5
>200

>200
50
100
100
50
100

12.5
3.13
25
12.5
6.25
200

12.5
3.13
6.25
3.13
6.25
>200
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(BCG) for 30 to 120 minutes, the cells were harvested and then washed to remove any
unreacted probe. The cells were then mechanically lysed and separated into two fractions
based upon molecular weight through the use of centrifugal 2,000 Daltonmolecular
weight cut-off filters. These heavy and light fractions were then reacted or “clicked” to
one of two reporters; a fluorescent tag for the LC analysis of the light fractions (Figure
52) or a biotinylated linker to facilitate affinity separation of the proteins contained in the
heavy fractions. (Figure 53).
The unreacted florescent azide elutes very near the conjugation product. To
evaluate the chemical cycloaddition process a click probe (Lee-1595 is illustrated in the
fluorescence spectra below) was allowed to react with the fluorescent azide in PBS. The
unreacted fluorophore elutes last (TR 17.933) slightly following the elution of the
cycloaddition product (TR 17.525). While the two compounds were closely eluting even
on a longer (BPD) method, fractions were successfully collected and their identities
conformed via MS. (Figure 54) Analytical HPLC fluorescence spectra of 1595
conjugation products evaluating the use of MeOH (Figure 55) and ACN (Figure 56)
organic mobile phases, MeOH was chosen due to the increases in absolute intensity,
despite its slightly poorer chromatographic properties.
Figure 57 illustrates the results of the click conjugation reaction product
cycloaddition proceeded to near 100% completion. Figure 58 illustrates the fluorescence
spectra from the cycloaddition reaction in BCG extract. In this spectra below,1 the parent
(drug + fluorophore) conjugation product can be identified through the use of retention
times (TR 6.93). A number of fluorescently tagged, presumably more polar (more early
eluting) molecules can be seen with significant fluorescent peaks appearing at TR 6.08,
6.38, 6.61, respectively. As these fluorescent peaks do not elute with either the unbound
fluorophore or the fluorescently tagged drug conjugate, they must be fluorescently tagged
molecules of an unknown nature. An effort was made to collect fractions but the short
half-life of the potential metabolic products and dilute nature of the fractions proved to
greatly complicate MS detection.
The “light” products were then separated and analyzed via reverse phase
fluorescence HPLC. The heavy products were “pulled down” using solid phase supported
streptavatin beads and run out on SDS/PAGE gels. The gels were then robotically
harvested, digested and analyzed via nanospray LC/MS, the resultant data was submitted
for database searching. We are currently in the process of analyzing the “heavy fraction”
search results in hopes of identifying the ultimate target of our nitrofuran based
compounds. A number of LC runs seem to confirm the presence of low level fluorescent
metabolites in the click tagged (light) bacterial fractions. We are now faced with the task
of identifying these short-lived compounds; we have attempted the “semi-analytical”
HPLC fractionation of the fluorescence peaks, then UPLC/MS of the resultant fractions.
This offline method has not proven successful; the compounds seem to degrade between
the purification and MS steps, while we currently do not have an UPLC/MS with a
fluorescence detector, we are in the process of correcting this potential shortcoming.
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Figure 54.
Products

Fluorescence Spectra of Semi-Analytical HPLC Separation of Click
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Figure 55.
Analytical HPLC Separation of 1595 Conjugation Products with
MeOH Organic Mobile Phase
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Figure 56.
Analytical HPLC Separation of 1595 Conjugation Products with ACN
Organic Mobile Phase
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Figure 57.
Analytical HPLC Analytical Fluorescence Spectra of 1521
Fluorometric Conjugation Product in PBS + Catalytic TBTA
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Figure 58.
Analytical HPLC Fluorescence Spectra of 1521 following BCG
Incubation and Click Tagging
NOTE: Numerous presumably metabolic products can be visualized; however, the very
dilute analytes made further offline MS analysis impossible.
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Our laboratory has currently synthesized six nitrofuran based “click” tags for use
in the next iteration of this experiment. (Figures 59-64) Overall the MIC’s of the click
tagged compounds are quite similar to their non-derivatized parents (Table 2).
Click Pulldown Conclusions and Discussion
The click chemistry portion of this experiment proved to be quite successful
despite initially suffering from low yields. The addition of catalytic amounts of tris[(1benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) (Figure 65) was found to greatly
increase click yields through the stabilization of the copper/azide intermediate.178 The
probes also retained reasonable antimicrobial activity upon addition of the acetylene tag.
The shortcoming lied in that when our laboratory initially conducted these experiments
we did not yet have access to a high sensitivity mass spectrometer.
The initial analytical workflow relied on the use of an HPLC equipped with only a
UV/Vis and fluorescence detector. The hope was that the resultant fluorescent signals
would be sufficient to collect small fractions of effluent using the fluorescence signal as a
gate. While we were able to detect fluorescent components in the supernatant samples,
we were unable to identify them any further, due to both the metabolites relatively short
half-life and the incredible dilution factor involved in the collection of fractions.
The high mass click tagging system proved to be successful, it just failed to
identify any novel proteins or suggest alternative modifications to previously known
targets. However, I still remain quite confident in the utility of this analytical technique,
as both tagging strategies were successful on their own right. The light fractionation
project ultimately failed due to lack of instrumentation not experimental design. The
high mass tagging worked; it just failed to find anything new.
In light of recent additions, to both departmental instrumentation, and due to an
increased knowledge of the nitrofuran bacterial targets we are currently preparing to
revisit the light click tagging procedure for the identification of both nitrofuran and other
metabolites.
While this project has perhaps been the most challenging to date, I also believe it
holds the most future promise as a tool uniquely suited to elucidate previously unknown
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Table 2.

In-vitro ADME and MIC of Click Probes

Structure

Mtb
MIC

Solubility
(pH 7.4)
ug/mL

Permeability
-6
(10 cm/s)

t1/2
(human)

t1/2
(mouse)

Protein
binding
(human)

Protein
binding
(mouse)

0.2

22.6

177.9

1.65

0.34

90.4

94.6

0.2

24.8

39.9

2.88

0.56

72.0

70.0

<0.0001

3.4

363.3

>50

0.93

98.1

98.5

0.025

5.1

96.5

23.64

0.74

91.0

82.6
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Structure of TBTA
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small molecule bacterial metabolic pathways for bioactivated drugs. We have shown a
high yielding cycloaddition can be performed in a variety of solutions through the
addition of catalytic amounts of TBTA. We have also been able to visualize fluorescent
conjugations products upon incubation with BCG. Unfortunately, our limited analytical
instrumentation coupled with the relatively unstable nature of the metabolites prevented
the acquisition of fluorescence associated mass spectrometric values.
To address this shortcoming, I am currently in the process of coupling an ultrahigh resolution fluorescence detector (Shimadzu RF-10AXL) to our newly acquired
UPLC-qTOF. Through the use of this specially hyphenated instrument I am confident we
will finally achieve fluorescence and mass spectrometric data simultaneously. These two
highly sensitive analytical techniques applied in concert will allow the identification and
ultimate structural elucidation of the “light” click fragments which has eluded us to date.
Upon significant validation, I believe these Click-HRMS techniques will serve to
revolutionize the way not only our laboratory accesses scaffold stability, but serve to
advance the field of antimicrobial research through the elucidation of previously
unknown bacterial xenobiotic detoxification strategies.
The most immediate ways I would like to further this project include repeating the
BCG nitrofuran experiment with our new instrument as well as further investigating the
metabolism of our click probes in MRSA. In primary screening our click tagged
nitrofuranal compounds displayed significant efficacy against MRSA (Table 3). As we
are very near establishing a pipeline for the click pulldown and analysis of metabolic
products it would be quite simple to “change bugs” in our experimental procedure. I
believe these insights could prove significant in a number of ways, first as a cross
validation of our analytical processes. Secondly, I would like to determine if nitrofuran
metabolism differs between bacterial species? This line of analysis could also serve to
evaluate the target of mycolactone as very little is currently known regarding the necrotic
processes at work in Buruli ulcer. Once current handling and archival difficulties are
addressed, as I believe they soon will be, I would like to further investigate mycolactone
induced necrosis through the development of acetylene tagged mycolactone (Figures 66
and 67). The processes underlying the host response and detoxification of mycolactone
are currently unknown.
I would also like to investigate the metabolic processes involved in the bacterial
detoxification of linezolid, an oxazolidinone antibacterial agent proven to be effective in
the treatment of vancomycin-resistant enterococci (VRE) as well as MRSA. In many
ways linezolid constitutes our last line of defense against clinical presentations of gram
positive vancomycin resistant bacteria associated skin and soft tissue infections (SSTI).
While the approval of linezolid was heralded as a significant breakthrough in the battle
against drug resistant bacterium, numerous clinical presentations of linezolid resistant
infections have been reported.179 From the synthetic standpoint an acetylene tagged
linezolid should be relatively easy to synthesize. This novel, click conjugated probe
(Figure 68) could then prove instrumental to the interrogation of the linezolid bacterial
bioremediation process and afford new insights into the metabolic mechanisms at work in
linezolid resistant enterococci and staphylococcus.
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Experimental Methods
The experimental methods developed throughout this chapter are outlined below.
HRMS Stability Analysis Methods
Preparation of Urinalysis Samples
All urine samples were thawed at room temperature and briefly vortexed to
homogenize. 50 µL of each urine sample were transferred to microcentrifuge tubes
containing 200µL of CH3OH and proteins allowed to precipitate at -20◦C for 20 minutes.
The suspensions were clarified via ultracentrifugation and 80 µL of the supernatant was
removed for UPLC/MS analysis.
UPLC/MS Analysis
LC/MS analyses were performed on both a Waters Acquity UPLC-TQD and a
Waters Acquity UPLC-qTOF. All dry analytes were solvated in CH3OH and filtered prior
to analysis; liquid analytes were diluted in the same and filtered. Separations were
achieved at 0.5 mL/min via a 5 minute gradient elution from 95% H2O + 0.1% Formic
Acid to 95% ACN + 0.1% Formic Acid as follows. The first 30 seconds were held at the
starting conditions then ramped to 40% organic over two minutes followed by a ramp to
95% organic an additional two minutes then followed by a 30 second stop at the 95%
organic before returning to re-equilibrate. A Waters Acquity C18 BEH 1.7µ x 50 x
3.0mm column was maintained at 40◦C through-out the elution series. Detection was
achieved via PDA and MS.
Click Pull-down Methods
Click Pulldown in BCG
BCG stocks were grown in liquid agar to an OD of 0.5. Bacterial stocks were
transferred in to culture flasks, administered click probes at 10x MIC and incubated at
37◦C for 48 hours, then harvested via centrifugation. The pellets were twice washed in
PBS and centrifuged. The pellets were then resuspended in 700µL of PBS for beadbeating. The resultant solution was clarified via centrifugation and the supernatant
decanted. The supernatant was separated in two fractions via size exclusion membrane
(2,000 amu). All fractions were collected and stored frozen until the completion of the
experiment.
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All samples were thawed at room temperature and briefly vortexed to
homogenize. The extracts were then transferred into a microwave tube containing of 1:1
CH3OH:H2O (2.5mL) 100uL of previously prepared (100µg/mL in CH3OH) tag was add
to the tube with a catalytic quantity of TBTA. The samples were allowed to react stirring
slowly in a 37◦C oil bath overnight. Upon completion the organic solvents were removed
from the reaction mixture via rotovap under soft vacuum the aqueous solutions were
filtered and vialed for UPLC or SDS/PAGE Analysis.
HPLC Separation of Click Conjugation Products
All samples were dissolved in GC/MS grade CH3OH and transferred to
autosampler vials. Separations were achieved on a Grace Davidson Prevail C18 Select
Rocket Column (53mm x 7mm x 3µm) at 50◦C, flowing 2.5 mL/min of H2O + 0.1%
Formic acid (A) and ACN+ 0.1% Formic Acid (B). The first 12.5 minutes were
maintained at 10% organic followed by a linear ramp to 95% organic over 45 minutes
then held at high organic for an additional 12.5 minutes resulting in a 1 hour total
chromatographic elution. All fractions were collected in glass tubes then turbovaped to
dryness. The samples flagged through UV and ELSD were reanalyzed via UPLC/MS.
Fractions found to contain lipid moieties were divided 1:10 for bioanalysis and archival
respectively.
MS Identification of Heavy Fractions
The protein gel bands were reduced and alkylated with iodoacetamide and
digested with Trypsin. Mass spectrometric analysis was performed using an LTQ
Orbitrap Mass Spectrometer from Thermo Electron (San Jose, CA). This instrument
employs electrospray ionization (ESI), in conjunction with an Orbitrap mass analyzer.
The digest was introduced into the instrument via on line chromatography using reverse
phase (C18) ultra-high pressure liquid chromatography on the nanoAcquity (Waters,
MA). The column used was a Waters BEHC18 with an I.D. of 75um and bed length of
10cm. The particle size was 1.7um. Peptides were gradient eluted into the linear ion trap
through a non-coated spray needle with voltage applied to the liquid by increasing the
concentration of acetonitrile. Data acquisition involved acquiring the peptide mass (MS)
spectra followed by fragmentation of the peptide to produce MS/MS spectra that provides
information about the peptide sequence. Database searches were performed using
LTQ.raw files in combination with the Mascot search engine. Protein/peptide
assignments were made on the basis of MS/MS spectra.
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APPENDIX A. MASS DIFFERENTIAL OF COMMON METABOLITES
The following tables serve to illustrate the nominal mass change(s) indicative of
common metabolic transformations both via MS180 (Table 3) and MS/MS181 (Table 4)
scanning modes.
Table 3.
Differences

Common Metabolic Reactions and Their Associated Nominal Mass
Conjugate
Acetylation
Carbon Hydroxylation
Demethylation
Epoxidation
Glucuronidation
Glutamine Conjugation
Glycine Conjugation
Methylation
N-Hydroxylation
N-Oxidation
Oxidative Desulfuration
Phosphorus Oxidation
Sulfation
Taurine Conjugation
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m/z
42
16
-14
16
176
145
57
14
16
16
-32
16/17
80
107

Table 4.

Characteristic Fragments of Drug Conjugation via MS/MS Scanning

Conjugate
Aliphatic Sulfates
Aliphatic-GSH
Aryl-GSH
Carnitine Butyl Esters
Coenzyme A Thioesters
(-)
Coenzyme A Thioesters
(+)
Glucuronides
N-Acetylcysteines
Phenolic sulfates
Phosphates
Sulfinates
Sulfonates
Taurines
Taurines

Ionization Mode
Negative
Positive
Positive
Positive

MS/MS Scan
Precursor
Neutral Loss
Neutral Loss
Precursor

Negative

Precursor

329,358

Positive
Both
Negative
Positive
Negative
Negative
Negative
Positive
Negative

Precursor
Neutral Loss
Neutral Loss
Neutral Loss
Precursor
Neutral Loss
Precursor
Precursor
Precursor

428
176
129
89
63,79
64
81
126
339,358
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Mass
97
129
275
103

APPENDIX B. STRUCTURES OF FAME GC/MS PEAKS #2 - #11
O
O
Chemical Formula: C11H22O2
O
O
Chemical Formula: C13H26O2
O
O
OH
Chemical Formula: C11H22O3

O
O

Chemical Formula: C15H30O2
O
O
Chemical Formula: C17H34O2

O
O

Chemical Formula: C19H38O2

O
O

Chemical Formula: C19H36O2
O
O
Chemical Formula: C21H42O2
O
O
Chemical Formula: C21H40O2

O
O

Chemical Formula: C23H46O2
O
O
Chemical Formula: C23H44O2
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APPENDIX C. SUPPORTING PK INFORMATION

Figure 69.

HRMS Identification of Nitazol Metabolite
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Figure 70.

HRMS Idenification of PD30 Metabolite
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Figure 71

Quantification of Nitazol Metabolite

124

Figure 72.

Structure of Cetrorelix
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Figure 73.

HRMS Stability Study of Cetrorelix
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Table 5.

Calculated Cetrorelix Stability
Sample Lot
5-May-11

Sample
T1
T2
T3

Peak Area
139899
136344
141620

T4
T5
T6

142874
141716
139841

6-May-11

Mean (T)

140382

After 7 Days

O1
O2
O3

Mean (O)

71464
71580
69584
70876

Blank

B1
B2
B3

59
67
48

Mean Blank

58

Mean Lifespan (hrs)

192

Mean Degradation (% avg)

0.504673696

Mean Lifespan (Calculated)

190.221921
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APPENDIX A.

MASS SPECTROMETER PARAMETERS

TQD MS1 Parameters
Instrument Parameters - Function 1:
Parameter File - C:\MassLynx\Jerrod_Quant.PRO\ACQUDB\JSS_Quant1.ipr
Polarity ES+
CalibrationDynamic 1
Capillary (kV)
3.00
2.98
Cone (V) 75.00
77.41
Extractor (V)
3.00
2.20
RF (V)
0.10
Source Temperature (°C)
150
148
Desolvation Temperature (°C) 300
300
Cone Gas Flow (L/Hr)
40
40
Desolvation Gas Flow (L/Hr)
500
498
Collision Gas Flow (mL/Min) 0.10
0.01
LM 1 Resolution
9.81
HM 1 Resolution
15.25
Ion Energy 1
0.35
MS Mode Entrance 50.00
MS Mode Collision Energy
3.00
MS Mode Exit
50.00
MSMS Mode Entrance
50.00
MSMS Mode Collision Energy 75.00
MSMS Mode Exit
50.00
LM 2 Resolution
13.74
HM 2 Resolution
15.25
Ion Energy 2
0.97
Gain
1.00
Multiplier -648.97
Active Reservoir
B
Engineers Settings:
MS1 Low Mass Position
519
MS1 High Mass Position
441
MS1 Low Mass Resolution
518
MS1 High Mass Resolution
803
MS1 Resolution Linearity
750
MS1 High Mass DC Balance
-0
MS1 DC Polarity
Positive
MS2 Low Mass Position
520
MS2 High Mass Position
449
MS2 Low Mass Resolution
512
MS2 High Mass Resolution
689
MS2 Resolution Linearity
825
MS2 High Mass DC Balance
-0
MS2 DC Polarity
Positive
HM RF Lens Correction +
0
HM RF Lens Correction 0
Inter-scan delays:
Automatic Mode
MS 1 Delay Table:
R delay
<= 0.500 0.005
<= 1.200 0.010
<= 2.400 0.015
<= 6.000 0.020
<= 15.000 0.025
<= 25.000 0.028
> 25.000 0.030
MS 2 Delay Table:
R delay
<= 2.000 0.005
<= 4.000 0.008
<= 7.000 0.010
<= 10.000 0.012
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<= 20.000 0.014
> 20.000 0.016
-- PUMP -Waters Acquity SDS
Run Time: 5.00 min
Comment:
Solvent Selection A: A1
Solvent Selection B: B1
Low Pressure Limit: 0 psi
High Pressure Limit: 15000 psi
Solvent Name A: Water
Solvent Name B: Acetonitrile
Switch 1: No Change
Switch 2: No Change
Switch 3: No Change
Seal Wash: 5.0 min
Chart Out 1: System Pressure
Chart Out 2: %B
System Pressure Data Channel: No
Flow Rate Data Channel: No
%A Data Channel: No
%B Data Channel: No
Primary A Pressure Data Channel: No
Accumulator A Pressure Data Channel: No
Primary B Pressure Data Channel: No
Accumulator B Pressure Data Channel: No
Degasser Pressure Data Channel: No
[Gradient Table]
Time(min) Flow Rate %A %B Curve
1. Initial 0.500 90.0 10.0
2. 0.50 0.500 90.0 10.0 6
3. 3.00 0.500 5.0 95.0 6
4. 4.50 0.500 5.0 95.0 6
5. 4.80 0.500 90.0 10.0 6
Run Events: Yes
-- DETECTOR -Waters Acquity PDA
PDA Detector Type: UPLC LG 500 nm
Lamp: On
Sampling Rate: 20 points/sec
Filter Time Constant: 0.1000 sec
Exposure Time: Auto msec
Interpolate 2nd order filter (340nm) Region: No
Use UV Blocking Filter: No
3D Channel...
Range: 190 - 400
Resolution: 1.2 nm
Compensation Reference 2D Parameters...
Range: 310 - 410
Initial Switch 1: No Change
Initial Switch 2: No Change
-- AUTOSAMPLER -Waters Acquity AutoSampler
Run Time: 5.00 min
Comment:
Load Ahead: Disabled
Loop Option: Partial Loop With Needle Overfill
LoopOffline: Disable
Weak Wash Solvent Name:
Weak Wash Volume: 1000 uL
Strong Wash Solvent Name:
Strong Wash Volume: 1000 uL
Target Column Temperature: 40.0 C
Column Temperature Alarm Band: Disabled
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Target Sample Temperature: Off C
Sample Temperature Alarm Band: Disabled
Full Loop Overfill Factor: Automatic
Syringe Draw Rate: Automatic
Needle Placement: 8.0
Pre-Aspirate Air Gap: Automatic
Post-Aspirate Air Gap: Automatic
Column Temperature Data Channel: No
Ambient Temperature Data Channel: No
Sample Temperature Data Channel: No
Sample Organizer Temperature Data Channel: No
Sample Pressure Data Channel: No
Switch 1: No Change
Switch 2: No Change
Switch 3: No Change
Switch 4: No Change
Chart Out: Sample Pressure
Sample Temp Alarm: Disabled
Column Temp Alarm: Disabled
Run Events: Yes
Needle Overfill Flush: Automatic
Sample Loop Size: 10.0
Sample Run Injection Parameter
Injection Volume (ul) - 7.50
Cycle time (secs):
-1.000
Scan duration (secs): 0.15
Interscan delay (secs): -1.00
Retention window (mins): 0.000 to 5.000
Ionization mode:
ES+
Data type:
Accurate Mass
Function type:
Scan
Mass range:
300 to 900
Function 2
Scans in function:
6001
Function type:
Diode Array
Wavelength range ( nm ) : 190 to 400
TQD MS/MS Parameters
Instrument Parameters - Function 1:
Parameter File - C:\MassLynx\Jerrod_Quant.PRO\ACQUDB\JSS_Quant1.ipr
Polarity ES+
CalibrationDynamic 2
Capillary (kV)
3.00
2.98
Cone (V) 75.00
76.43
Extractor (V)
3.00
2.69
RF (V)
0.10
Source Temperature (°C)
150
148
Desolvation Temperature (°C) 300
300
Cone Gas Flow (L/Hr)
40
39
Desolvation Gas Flow (L/Hr)
500
498
Collision Gas Flow (mL/Min) 0.10
0.10
LM 1 Resolution
9.81
HM 1 Resolution
15.25
Ion Energy 1
0.35
MS Mode Entrance 50.00
MS Mode Collision Energy
3.00
MS Mode Exit
50.00
MSMS Mode Entrance
50.00
MSMS Mode Collision Energy 50.0
MSMS Mode Exit
50.00
LM 2 Resolution
13.74
HM 2 Resolution
15.25
Ion Energy 2
0.97
Gain
1.00
Multiplier -648.97
Active Reservoir
B
Engineers Settings:
MS1 Low Mass Position
519
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MS1 High Mass Position
441
MS1 Low Mass Resolution
518
MS1 High Mass Resolution
803
MS1 Resolution Linearity
750
MS1 High Mass DC Balance
-0
MS1 DC Polarity
Positive
MS2 Low Mass Position
520
MS2 High Mass Position
449
MS2 Low Mass Resolution
512
MS2 High Mass Resolution
689
MS2 Resolution Linearity
825
MS2 High Mass DC Balance
-0
MS2 DC Polarity
Positive
HM RF Lens Correction +
0
HM RF Lens Correction 0
Inter-scan delays:
Automatic Mode
MS 1 Delay Table:
R delay
<= 0.500 0.005
<= 1.200 0.010
<= 2.400 0.015
<= 6.000 0.020
<= 15.000 0.025
<= 25.000 0.028
> 25.000 0.030
MS 2 Delay Table:
R delay
<= 2.000 0.005
<= 4.000 0.008
<= 7.000 0.010
<= 10.000 0.012
<= 20.000 0.014
> 20.000 0.016
-- PUMP -Waters Acquity SDS
Run Time: 5.00 min
Comment:
Solvent Selection A: A1
Solvent Selection B: B1
Low Pressure Limit: 0 psi
High Pressure Limit: 15000 psi
Solvent Name A: Water
Solvent Name B: Acetonitrile
Switch 1: No Change
Switch 2: No Change
Switch 3: No Change
Seal Wash: 5.0 min
Chart Out 1: System Pressure
Chart Out 2: %B
System Pressure Data Channel: No
Flow Rate Data Channel: No
%A Data Channel: No
%B Data Channel: No
Primary A Pressure Data Channel: No
Accumulator A Pressure Data Channel: No
Primary B Pressure Data Channel: No
Accumulator B Pressure Data Channel: No
Degasser Pressure Data Channel: No
[Gradient Table]
Time(min) Flow Rate %A %B Curve
1. Initial 0.500 90.0 10.0
2. 0.50 0.500 90.0 10.0 6
3. 3.00 0.500 5.0 95.0 6
4. 4.50 0.500 5.0 95.0 6
5. 4.80 0.500 90.0 10.0 6
Run Events: Yes
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-- DETECTOR -Waters Acquity PDA
PDA Detector Type: UPLC LG 500 nm
Lamp: On
Sampling Rate: 20 points/sec
Filter Time Constant: 0.1000 sec
Exposure Time: Auto msec
Interpolate 2nd order filter (340nm) Region: No
Use UV Blocking Filter: No
3D Channel...
Range: 190 - 400
Resolution: 1.2 nm
Compensation Reference 2D Parameters...
Range: 310 - 410
Initial Switch 1: No Change
Initial Switch 2: No Change
-- AUTOSAMPLER -Waters Acquity AutoSampler
Run Time: 5.00 min
Comment:
Load Ahead: Disabled
Loop Option: Partial Loop With Needle Overfill
LoopOffline: Disable
Weak Wash Solvent Name:
Weak Wash Volume: 1000 uL
Strong Wash Solvent Name:
Strong Wash Volume: 1000 uL
Target Column Temperature: 40.0 C
Column Temperature Alarm Band: Disabled
Target Sample Temperature: Off C
Sample Temperature Alarm Band: Disabled
Full Loop Overfill Factor: Automatic
Syringe Draw Rate: Automatic
Needle Placement: 8.0
Pre-Aspirate Air Gap: Automatic
Post-Aspirate Air Gap: Automatic
Column Temperature Data Channel: No
Ambient Temperature Data Channel: No
Sample Temperature Data Channel: No
Sample Organizer Temperature Data Channel: No
Sample Pressure Data Channel: No
Switch 1: No Change
Switch 2: No Change
Switch 3: No Change
Switch 4: No Change
Chart Out: Sample Pressure
Sample Temp Alarm: Disabled
Column Temp Alarm: Disabled
Run Events: Yes
Needle Overfill Flush: Automatic
Sample Loop Size: 10.0
Sample Run Injection Parameter
Injection Volume (ul) - 7.50
Function 1
Scans in function:
1659
Cycle time (secs):
-1.000
Scan duration (secs): 0.15
Interscan delay (secs): -1.00
Retention window (mins): 0.000 to 5.000
Ionization mode:
ES+
Data type:
Accurate Mass
Function type:
Daughters of 765.00
Mass range:
300 to 600
Collision Energy:
50.0
Function 2
Scans in function:
6001
Function type:
Diode Array
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Wavelength range ( nm ) : 190 to 400
HRMS Positive Mode Parameters
Function Parameters - Function 1 - TOF MS FUNCTION
Scan Time (sec)
0.500
Interscan Time (sec)
0.014
Start Mass
200.0
End Mass
900.0
Start Time (mins)
0.00
End Time (mins)
5.00
Data Format
Continuum
ADC Sample Frequency (GHz)
6.0
ADC Pusher Frequency (µs)
60.0
ADC Pusher Width (µs)
1.50
Use Tune Page Cone Voltage
NO
CV Ramp Start Voltage
15.0
CV Ramp End Voltage
50.0
Using Auto Transfer Collision Energy (eV) 6.000000
Sensitivity
Normal
Dynamic Range
Normal
Save Collapsed Retention Time Data
No
Use Rule File Filtering
No
Calibration
Dynamic 2
-- PUMP -Waters Acquity SDS
Run Time: 5.00 min
Comment:
Solvent Selection A: A1
Solvent Selection B: B1
Low Pressure Limit: 0 psi
High Pressure Limit: 15000 psi
Solvent Name A: Water
Solvent Name B: Acetonitrile
Switch 1: No Change
Switch 2: No Change
Switch 3: No Change
Seal Wash: 5.0 min
Chart Out 1: System Pressure
Chart Out 2: %B
System Pressure Data Channel: No
Flow Rate Data Channel: No
%A Data Channel: No
%B Data Channel: No
Primary A Pressure Data Channel: No
Accumulator A Pressure Data Channel: No
Primary B Pressure Data Channel: No
Accumulator B Pressure Data Channel: No
Degasser Pressure Data Channel: No
[Gradient Table]
Time(min) Flow Rate %A %B Curve
1. Initial 0.400 98.0 2.0
2. 0.50 0.400 98.0 2.0 6
3. 3.75 0.400 5.0 95.0 6
4. 4.50 0.400 5.0 95.0 6
5. 4.60 0.400 98.0 2.0 6
6. 5.00 0.400 98.0 2.0 6
Run Events: Yes
-- DETECTOR -Waters Acquity TUV
Run Time: 5.00 min
Wavelength Mode: Dual Wavelength
Lamp On: On
Channel A...
Comment:
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Wavelength: 254 nm
Sampling Rate: 2 points/sec
Data Mode: Absorbance A
Time Constant: 1.0000 sec
Auto Zero On Wavelength Change: Maintain Baseline
Auto Zero On Inject Start: Yes
Channel B...
Comment:
Wavelength: 220 nm
Sampling Rate: 2 points/sec
Data Mode: Absorbance B
Time Constant: 1.0000 sec
Auto Zero On Wavelength Change: Maintain Baseline
Auto Zero On Inject Start: Yes
Analog 1...
Sensitivity: 2.000 AUFS
Chart Polarity: Positive (+)
Voltage Offset: 0 mV
Enable Chart Mark: Yes
Analog 2...
Sensitivity: 2.000 AUFS
Chart Polarity: Positive (+)
Voltage Offset: 0 mV
Enable Chart Mark: Yes
Run Events: Yes
Pulse Width: 1.0 sec
Rect Wave Period: 0.2 sec
-- AUTOSAMPLER -Waters Acquity AutoSampler
Run Time: 5.00 min
Comment:
Load Ahead: Disabled
Loop Option: Partial Loop
LoopOffline: Disable
Weak Wash Solvent Name:
Weak Wash Volume: 1000 uL
Strong Wash Solvent Name:
Strong Wash Volume: 500 uL
Target Column Temperature: 37.0 C
Column Temperature Alarm Band: Disabled
Target Sample Temperature: Off C
Sample Temperature Alarm Band: Disabled
Full Loop Overfill Factor: Automatic
Syringe Draw Rate: Automatic
Needle Placement: Automatic
Pre-Aspirate Air Gap: Automatic
Post-Aspirate Air Gap: Automatic
Column Temperature Data Channel: No
Ambient Temperature Data Channel: No
Sample Temperature Data Channel: No
Sample Organizer Temperature Data Channel: No
Sample Pressure Data Channel: No
Switch 1: No Change
Switch 2: No Change
Switch 3: No Change
Switch 4: No Change
Chart Out: Sample Pressure
Sample Temp Alarm: Disabled
Column Temp Alarm: Disabled
Run Events: Yes
Needle Overfill Flush: Automatic
Sample Loop Size: 10.0
Sample Run Injection Parameter
Injection Volume (ul) - 5.00
Function 1
Scans in function:
581
Cycle time (secs):
0.514
Scan duration (secs): 0.50
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Interscan delay (secs): 0.01
Retention window (mins): 0.000 to 5.000
Ionization mode:
ES+
Data type:
Enhanced Mass
Function type:
TOF MS
Mass range:
200 to 900
Function 2
Scans in function:
601
Function type:
Diode Array
Wavelength range ( nm ) : 220 to 254
HRMS Negative Mode Parameters
Function Parameters - Function 1 - TOF MS FUNCTION
Scan Time (sec)
0.500
Interscan Time (sec)
0.014
Start Mass
200.0
End Mass
900.0
Start Time (mins)
0.00
End Time (mins)
5.00
Data Format
Continuum
ADC Sample Frequency (GHz)
6.0
ADC Pusher Frequency (µs)
60.0
ADC Pusher Width (µs)
1.50
Use Tune Page Cone Voltage
NO
CV Ramp Start Voltage
15.0
CV Ramp End Voltage
50.0
Using Auto Transfer Collision Energy (eV) 6.000000
Sensitivity
Normal
Dynamic Range
Normal
Save Collapsed Retention Time Data
No
Use Rule File Filtering
No
Calibration
Dynamic 2
-- PUMP -Waters Acquity SDS
Run Time: 5.00 min
Comment:
Solvent Selection A: A1
Solvent Selection B: B1
Low Pressure Limit: 0 psi
High Pressure Limit: 15000 psi
Solvent Name A: Water
Solvent Name B: Acetonitrile
Switch 1: No Change
Switch 2: No Change
Switch 3: No Change
Seal Wash: 5.0 min
Chart Out 1: System Pressure
Chart Out 2: %B
System Pressure Data Channel: No
Flow Rate Data Channel: No
%A Data Channel: No
%B Data Channel: No
Primary A Pressure Data Channel: No
Accumulator A Pressure Data Channel: No
Primary B Pressure Data Channel: No
Accumulator B Pressure Data Channel: No
Degasser Pressure Data Channel: No
[Gradient Table]
Time(min) Flow Rate %A %B Curve
1. Initial 0.400 98.0 2.0
2. 0.50 0.400 98.0 2.0 6
3. 3.75 0.400 5.0 95.0 6
4. 4.50 0.400 5.0 95.0 6
5. 4.60 0.400 98.0 2.0 6
6. 5.00 0.400 98.0 2.0 6
Run Events: Yes
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-- DETECTOR -Waters Acquity TUV
Run Time: 5.00 min
Wavelength Mode: Dual Wavelength
Lamp On: On
Channel A...
Comment:
Wavelength: 254 nm
Sampling Rate: 2 points/sec
Data Mode: Absorbance A
Time Constant: 1.0000 sec
Auto Zero On Wavelength Change: Maintain Baseline
Auto Zero On Inject Start: Yes
Channel B...
Comment:
Wavelength: 220 nm
Sampling Rate: 2 points/sec
Data Mode: Absorbance B
Time Constant: 1.0000 sec
Auto Zero On Wavelength Change: Maintain Baseline
Auto Zero On Inject Start: Yes
Analog 1...
Sensitivity: 2.000 AUFS
Chart Polarity: Positive (+)
Voltage Offset: 0 mV
Enable Chart Mark: Yes
Analog 2...
Sensitivity: 2.000 AUFS
Chart Polarity: Positive (+)
Voltage Offset: 0 mV
Enable Chart Mark: Yes
Run Events: Yes
Pulse Width: 1.0 sec
Rect Wave Period: 0.2 sec
-- AUTOSAMPLER -Waters Acquity AutoSampler
Run Time: 5.00 min
Comment:
Load Ahead: Disabled
Loop Option: Partial Loop
LoopOffline: Disable
Weak Wash Solvent Name:
Weak Wash Volume: 1000 uL
Strong Wash Solvent Name:
Strong Wash Volume: 500 uL
Target Column Temperature: 37.0 C
Column Temperature Alarm Band: Disabled
Target Sample Temperature: Off C
Sample Temperature Alarm Band: Disabled
Full Loop Overfill Factor: Automatic
Syringe Draw Rate: Automatic
Needle Placement: Automatic
Pre-Aspirate Air Gap: Automatic
Post-Aspirate Air Gap: Automatic
Column Temperature Data Channel: No
Ambient Temperature Data Channel: No
Sample Temperature Data Channel: No
Sample Organizer Temperature Data Channel: No
Sample Pressure Data Channel: No
Switch 1: No Change
Switch 2: No Change
Switch 3: No Change
Switch 4: No Change
Chart Out: Sample Pressure
Sample Temp Alarm: Disabled
Column Temp Alarm: Disabled
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Run Events: Yes
Needle Overfill Flush: Automatic
Sample Loop Size: 10.0
Function 1
Scans in function:
581
Cycle time (secs):
0.514
Scan duration (secs): 0.50
Interscan delay (secs): 0.01
Retention window (mins): 0.000 to 5.000
Ionization mode:
ESData type:
Enhanced Mass
Function type:
TOF MS
Mass range:
200 to 900
Function 2
Scans in function:
601
Function type:
Diode Array
Wavelength range ( nm ) : 220 to 254
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